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1. INTRODUCTION 
"For thousands of years we have pursued altered mental 
states and other-wordly insights, whether through prayer 
and meditation, through art or sexual ecstacy, or through 
psychoactive substances" (R.Campbell-Johnston, The 
Times, August 14, 1996). 
Drug addiction is defined as a behavioral syndrome consisting of compulsive 
pattern of drug use, characterized by overwhelming involvement with the use of 
a drug, the securing of its supply, and a high tendency to relapse after with­
drawal [abstinence] (Jaffe, 1975). In other words, in the case of addiction the 
use of a drug appears to dominate over behaviors that once had a higher value, 
the ones essential for the organism's survival and well-being included. This 
intrinsic feature of addiction is well characterized by the term motivational 
toxicity (Bozarth and Wise, 1985). 
In the contemporary world drug addiction has become a major health prob­
lem. Despite the vast amount of scientific information available, the ability of 
drugs to create addiction is still poorly understood, and research in this area is 
characterized by controversial findings. Furthermore, no effective treatment is 
available as yet. 
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2. REVIEW OF LITERATURE 
2.1. REINFORCEMENT THEORY 
The most popular approach has been the behavioristic one, that is, to analyze 
the addiction process within the framework of drug reinforcement theory 
(which is an extension of operant psychology). Accordingly, drug addiction is 
viewed as a behavior controlled by its consequences, which means that "... the 
behavior of drug taking is governed by the direct and immediate consequences 
of that behavior — drug administration and the ensuing pharmacological ac­
tions of the drug" (Bozarth, 1987). The term reinforcement is used in order to 
describe the relationship between the behavior and its consequences. By nature 
reinforcement can be either positive or negative. In the case of positive rein­
forcement the presentation of a stimulus (i.e., the drug) increases the frequency 
(or probability) of the behavior that presentation of the stimulus is contingent 
upon; whereas negative reinforcement refers to a situation in which the fre­
quency of the behavior is increased by the removal of the stimulus (e.g., with­
drawal syndrome). It is important to note that reinforcement merely describes 
the changes in the probability of behavior and does not offer any physiological 
or psychological explanations to this. 
Reward is another term that is widely used in the present context. It is, un­
fortunately, somewhat ill-defined and therefore used in the literature in many 
different meanings. Many researchers refer to reward interchangeably with re­
inforcement, and the present study will do the same. 
2.2. PRINCIPAL MODELS OF DRUG ADDICTION 
There are two general models of drug addiction that have evolved from rein­
forcement theory. According to the negative reinforcement model, addictive 
behavior (drug seeking and drug taking) is sustained because of the state that is 
alleviated by drugs. In this model the central role is given to the aversive con­
sequences of drug withdrawal. The second model concentrates on the positive 
reinforcing properties of a drug, asserting that addictive behavior is sustained 
not because of the condition that the drugs remove or lessen, but because of the 
state the drugs produce. 
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Traditional negative reinforcement model, focusing on withdrawal and tol­
erance, though having predominated previously, has been challenged both ex­
perimentally and clinically (for discussion see Wise and Bozarth, 1987; Robin­
son and Berridge, 1993). For example, as noted by Wise and Bozarth (1987), 
"physical dependence is neither a necessary nor sufficient condition for drug 
addiction". This is not to deny any role at all for the withdrawal distress in ad­
dictive behavior, but it is evidently not the most important factor. In fact, ad­
diction is nowadays regarded as an integrated process, containing both posi­
tively, and negatively reinforcing components; however, a substantial body of 
evidence suggests an intrinsic role for positive reinforcing properties of drugs 
(Wise and Bozarth, 1987; Bozarth, 1994). These have been attributed to the 
drug-induced pleasurable effects (e.g., Wise, 1987), yet the question is far from 
clearness. Thus, it is currently generally accepted that drugs may serve as posi­
tive reinforcers, but whether the underlying reason is hedonic by nature or, for 
instance, a relatively autonomic drug craving as proposed by Robinson and 
Berridge (1993), remains a matter for discussion. 
2.3. ROLE OF SENSITIZATION 
Some behavioral effects (e.g., locomotor activation) of opioids and psychomo­
tor stimulants are increased upon repeated intermittent administration. Such a 
phenomenon, called behavioral sensitization, is characteristic of many other 
addictive drugs as well (for review see Robinson and Berridge, 1993). Moreo­
ver, the neural substrates that mediate behavioral sensitization, at least to some 
extent coincide with those mediating the reinforcing properties (see below). It 
is unclear, however, whether behavioral sensitization reflects sensitization to 
the reinforcing properties of drugs. For instance, in the presence of sensitization 
to psychomotor effects of opioids, their positive reinforcing properties have 
been shown to be unchanged (Martin et al., 1988) or to exhibit tolerance 
(Shippenberg et al., 1988) or sensitization (Lett, 1989). Thus, the role of sensi­
tization is fairly unclear hitherto, though some researchers suggest it be a major 
determinant of drug addiction (Lett, 1989; Robinson and Berridge, 1993) 
2.4. ANIMAL MODELS OF DRUG ADDICTION 
Most drugs that are addictive in humans can serve as reinforcers in other mam­
mals. This fact refers to the involvement of brain mechanisms common to all 
mammals; on the other hand, it justifies the most widely implemented ap­
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proach, that is, to study drag addiction using animal models that involve posi­
tive reinforcement processes. The following short description is restricted to the 
three major experimental paradigms, place conditioning (or, more exactly, con­
ditioned place preference if one is concerned with positive reinforcement), drug 
self-administration, and intracranial self-stimulation. There are, of course, other 
methods in use, as for instance, drug discrimination. This method is unspecific 
to positive reinforcement, for besides the reinforcing properties, a myriad of 
other effects (as in the case of opioids are analgesia, changes in the autonomic 
nervous system, e.t.c.) could be responsible for stimulus cues. However, there 
appears to be a rather good concordance between the drug discrimination stud­
ies and human addiction liability (Bozarth, 1987). 
Conditioned place preference: In this paradigm the classical (Pavlovian) 
conditioning is involved. The test apparatus is typically a box consisting of two 
distinct compartments, which usually differ in visual, tactile and/or olfactory 
cues, and may be connected by a "neutral" section. The drug administration is 
repeatedly paired with one of the compartments, whereas the other one is paired 
with the injections of drag vehicle; later the drag-free animals are given free 
choice between both compartments. The drag is presumed to be positively rein­
forcing if the animals increase the time spent in the compartment that was asso­
ciated with the drag. Thus, in the case of conditioned place preference the drag 
acts as an unconditioned stimulus and the drag-related environment as a condi­
tioned one; i.e., the environment acquires reinforcing properties through condi­
tioning. 
Conditioned place preference is relatively quick and simple, and thus proba­
bly the most valuable method to preliminarily screen the drags for addiction 
liability, as well as in the development of new compounds in the treatment of 
addiction. Further, the method appears to be specific for positive reinforcing 
effects of drags. Because the animals are tested in an undragged state, the 
drag's direct influence on sensory and motor processes may be ruled out. Other 
considerable alternatives are in some instances, the antiaversive properties of 
drags (see below), and the effect of novelty, the significance of which, how­
ever, has been challenged by several studies (Mucha et al., 1982; Mucha and 
Iversen, 1984). 
There are two principal ways to ran place conditioning, the so called unbi­
ased and biased (or baknced and unbalanced) paradigms. In the case of the 
latter paradigm the animals exhibit an initial preference for one of the com­
partments, whereas in the former one it is absent. The biased type of procedure 
has been a matter for discussion because antiaversive rather than positively re­
inforcing properties of a given drag may be regarded as determinative (van der 
Kooy, 1987). Yet, the problem with the unbiased procedure is that it often ap­
pears to involve additional biases rather than removing the bias, making thus 
the situation even more complicated (Bozarth, 1987). An optimal way has been 
proposed to counterbalance the drag treatment between the nonpreferred and 
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preferred sides (Bozarth, 1987). With opioids, however, the experiments com­
paring the biased and counterbalanced procedures have provided consistent re­
sults (Blander et al, 1984; Mucha and Iversen, 1984). 
Drug self-administration: There are several self-administration procedures, 
which comprehend intravenous, intracranial, oral, and some others. Of these, 
the intravenous self-administration has been the most widely used procedure. 
Intravenous self-administration can be viewed as an operant behavior, where 
the term operant indicates that the responses have defined reinforcing conse­
quences and are instrumental in the attainment of a goal (Stolerman, 1992). In 
this procedure the drug is available for the experimental animals via implanted 
catheters, and the response, usually the leverpress, is followed by a drug injec­
tion. The drug is thought to serve as a positive reinforcer if the drug responding 
is higher than the response on a control lever (which does not result in drug 
administration); if response rate is higher when compared to the animals re­
ceiving injections of drug vehicle; or if the response rate is higher than in yoked 
controls, i.e., the animals receiving drug injection simultaneously with rein­
forced animals but independently of their own lever-pressing behavior (Yokel, 
1987). 
Intravenous self-administration is the most direct method to study drug rein­
forcement and has a high degree of validity. Though with some exceptions, 
drugs that are abused by humans serve as positive reinforcers in experimental 
animals in this paradigm (Yokel, 1987). On the other hand, the paradigm has 
some disadvantages in that it is sensitive to non-specific drug effects such as 
the influence on motor activity. Other problems are of a technical nature, for 
the intravenous preparation is relatively difficult to maintain, and the method is 
rather time-consuming (weeks or sometimes months of testing may be required 
for response patterns to stabilize). 
Intracranial self-stimulation: This method is an indirect one. It involves 
training animals to work for electrical brain stimulation and determining the 
effects of drugs on this behavior. The drugs that serve as positive reinforcers 
appear to enhance or facilitate intracranial self-stimulation. This effect can be 
expressed either by the increased rate of lever-pressing in the case of fixed in­
tensity brain stimulation, or as a lowering of current thresholds for brain stimu­
lation. Such an enhancement of intracranial self-stimulation behavior has been 
demonstrated for practically all known drugs of abuse (Bozarth et al., 1980). 
The problem with the method is that its neurochemical basis is relatively poorly 
understood. Furthermore, it may prove to be sensitive to the factors other than 
positive reinforcement. Among these are a nonspecific, stimulation produced 
energization and other manipulations that influence performance capacity, re­
lief of anxiety or pain (Liebmann, 1989). There is, however, a reliable correla­
tion between the positive reinforcing properties of drugs and their facilitative 
effect on intracranial self-stimulation behavior; likewise, the overall concor­
dance with human addiction liability data is very good (Bozarth, 1987). 
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2.5. POSITIVE REINFORCING PROPERTIES OF MORPHINE: 
NEUROCHEMICAL BASIS 
It is nowadays generally accepted that the drugs may serve as positive reinforc­
ers because of their interaction with the endogenous reinforcement mechanisms 
in the brain (or, reward pathways as they are widely called; e.g., Wise, 1987; 
Koob 1992). An important fact is that the same pathways appear to govern the 
organism's normal behavior such as eating, drinking, mating behavior, preda­
tory attack, and nest building (Glickman and Schiff, 1967; Stellar et al., 
1979)— the acts essential for individual and species survival. The following 
short review is concerned with the two major substrates, the endogenous opioid 
systems and the mesotelencephalic dopamine, which make up the endogenous 
reward pathways for many addictive drugs, opioids and psychomotor stimulants 
included (Koob, 1992). The role of a glutamate-related neurotransmitter, free 
radical gas nitric oxide, is also discussed. Certainly, other neurotransmitter 
systems are significantly involved, as, for instance, serotonin. This, however, 
remains beyond the scope of the present study. 
The part of our work that concerns dopamine, involves the experiments with 
cocaine. Though the initial idea was to use cocaine as a reference psychomotor 
stimulant, it proved to be of great interest by itself. The dopaminergic mecha­
nisms of cocaine reinforcement have been well demonstrated using the intrave­
nous self-administration paradigm but not so clearly as far as the place condi­
tioning is concerned. Therefore, also this problem will be briefly discussed. 
2.5.1. Role of opioid receptors 
The endogenous opioid systems, which are distributed throughout the central 
nervous system, constitute three distinct functional systems designated accord­
ing to their precursor molecules: ß-endorphin from proopiomelanocortin, 
enkephalins from proenkephalin, and dynorphins from prodynorphin (for re­
view see Khachaturian et al, 1993). These peptides exert their physiological 
actions by interacting with various classes of opioid receptors (see below), 
which are present both on pre- and postsynaptic membranes of opioidergic and 
their target neurons. There is a wide variety of physiological functions that ap­
pear to be influenced by opioidergic neurotransmission. Among these are 
modulation of nociceptive response to painful stimuli and stressors, reward, 
homeostatic and adaptive functions as eating, drinking, and thermoregulation 
(Koob, 1992; Khachaturian et al, 1993). 
Three main types of opioid receptors have been characterized pharma­
cologically: JLL, 8, and K (Lord et al., 1977; Martin et al., 1976), which according 
to the recent cloning studies belong to the family of seven transmembrane G-
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protein-coupled receptors (Mansour et al., 1995). Of these, the receptor is 
regarded as the primary site mediating the effects of opioids as morphine, her­
oin, and methadone. Thus, these drugs exert their actions, including positive 
reinforcement, mainly (but not exclusively) via activation of the (i receptor (Di 
Chiara and North, 1992). 
Binding studies have identified two subtypes of receptor, one with a high 
affinity to both morphine and enkephalins (|Lil), and another with a lower affin­
ity that binds morphine far more potently than enkephalins {\\2\ Wolozin and 
Pasternak, 1981). The physiological roles of these subtypes have mainly been 
characterized with opioid antagonist naloxonazine that is selective for (ill re­
ceptor (Pasternak and Wood, 1986). Naloxonazine antagonizes a variety of 
morphine effects including analgesia, without affecting the other ones such as 
respiratory depression (Pasternak and Wood, 1986). Further evidence suggests 
that the opioid analgesia in supraspinal level be mediated by JLII receptor, 
whereas the spinal analgesia and the respiratory depression are mediated by |x2 
receptor (Ling et al., 1985; Paul et al., 1989). 
There is data available showing that the jll receptor has no determining role 
in many signs of morphine withdrawal (Ling et al., 1984), which means that 
this subtype is apparently not involved in the negative reinforcing properties of 
opioids. It thus appears that the physical dependence and respiratory depression 
can be separated from opioid analgesia. An intriguing question is, which of the 
(i. receptor subtypes is involved in positive reinforcement, or in other words, 
whether one can dissociate the |H-opioid's positive reinforcing properties from 
analgesia as well. Needless to say, the thing is of great practical value. Thus far 
the data have been rather equivocal: in a study by Suzuki et al. (1993) 
naloxonazine did not antagonize morphine-induced place preference in mice, 
yet a rather selective |J,1 agonist etonitazene (Moolten et al., 1993) can serve as 
a positive reinforcer in rats (Caroll and Meisch, 1979; Sala et al., 1992). 
Since the brain dopamine has been strongly implicated in opioid reinforce­
ment (see below), an important question concerns the commitment of (H recep­
tor subtypes in this matter. The current knowledge is fairly inconsistent, for 
naloxonazine did not affect morphine-induced increase in striatal and limbic 
dopamine metabolism (Wood and Pasternak, 1983; Piepponen and Ahtee, 
1995), yet it did partially antagonize the enhanced dopamine metabolism pro­
duced by 11 receptor agonist [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAGO; 
Latimer etal., 1987). 
As far as morphine is concerned, albeit relatively selective for jj. receptor, it 
has also some affinity to the 8 receptor (Corbett et al., 1993). Selective 8 re­
ceptor agonists are able to serve as positive reinforcers (Shippenberg et al., 
1987; Suzuki et al., 1991), and furthermore, there is a significant predominance 
of 8 receptors over the JLX type in the nucleus accumbens (Goodman et al, 1983; 
Mansour et al., 1988). Hence, in the case of morphine also the 8 receptor may 
15 
be a likely candidate for mediating the reinforcement process. Nevertheless, the 
issue is not clear and opposing results are available. For instance, the intracere­
bral administration of 8 receptor antagonist ICI 174,864 did not affect the place 
preference induced by morphine given ICV (Shippenberg et al, 1987). 
In contrast to |Lt and 8, the administration of selective agonists at K receptors 
exhibits negative reinforcing effects, for in the place conditioning paradigm the 
animals actively avoid the stimuli that were previously associated with these 
drugs (Mucha and Herz, 1985). Concerning morphine, peripheral K receptors 
have been proposed to mediate its aversive effect that occurred after condi­
tioning with a small dose (0.05 mg/kg) administered intraperitoneal^ (Bechara 
and van der Kooy, 1985; 1987). Also, the aversive properties of selective K ago­
nists were suggested to be brought about by peripheral receptors (Bechara and 
van der Kooy, 1987). Later studies, however, have demonstrated that the activa­
tion of K receptors in the central nervous system is sufficient to induce aversive 
effects (Bals-Kubik etal., 1989; 1993). 
2.5.2. Role of brain dopamine 
Dopaminergic substrate of opioid reinforcement: The mesotelencephalic do­
pamine has been proposed to serve as a common neural substrate mediating 
positive reinforcing properties of many addictive drugs (Wise and Bozarth, 
1987). Furthermore, the same substrate is critically involved in the phenomenon 
of behavioral sensitization. Current evidence refers more precisely to the im­
portance of the so-called mesolimbic dopamine system (Di Chiara and Im-
perato, 1988; Kaliwas et al, 1993). This system is formed by the cell bodies of 
A10 dopaminergic neurons in the ventral tegmental area (VTA) and their pro­
jections to the ventral striatum (nucleus accumbens). A common feature for 
many addictive drugs, including opioids and psychomotor stimulants, is their 
ability to enhance the mesolimbic dopaminergic transmission (Di Chiara and 
Imperato, 1988); on the other hand, drugs with aversive properties (e.g., ago­
nists at K opioid receptors) have an opposite effect. 
Behaviorally relevant doses of opioids enhance both the firing of the dopa­
minergic neurons in the VTA (Gysling and Wang, 1983; Matthews and Ger­
man, 1984) and the release of dopamine in the nucleus accumbens (Di Chiara 
and Imperato, 1988). This effect is indirect by nature. Thus, the activity of A10 
dopaminergic neurons is modulated by inhibitory GABA-ergic interneurons, 
which express |H opioid receptors. Opioids hyperpolarize the GABA-ergic in­
terneurons via activation of receptors, and thus reduce the inhibitory control 
over A10 dopaminergic neurons (Gysling and Wang, 1983). 
The activity of the mesolimbic dopaminergic system is likewise regulated by 
a negative feedback mechanism that involves dopamine receptors located on 
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the dopaminergic cell itself, i.e., autoreceptors. Dopamine and exogenous do­
paminergic agonists inhibit the firing of most midbrain dopaminergic neurons 
by stimulating autoreceptors (Carlsson et al., 1975). Dopamine autoreceptors 
exhibit pharmacological characteristics of D2 or D3 receptors (White and 
Wang, 1984; Sokoloff et al., 1990; see below for dopamine receptor classifica­
tion). 
According to the mode of coupling to adenylate cyclase, dopamine receptors 
were originally divided into two main groups, designated as DI and D2 recep­
tors (Kebabian and Calne, 1979). The current cloning studies have extended 
this initial classification into Dl-like and D2-like receptor families, the former 
comprising DI and D5 receptors, and the latter D2, D3, and D4 receptors 
(Seeman and Van Tol, 1994). Several studies have demonstrated that dopamine 
receptor antagonists and lesions of dopaminergic neurons interfere with the 
opioid reinforcement (Bozarth and Wise, 1981; Spyraki et al., 1983; Smith, et 
al., 1985). More recent studies refer to the critical involvement of DI receptors 
(Shippenberg and Herz, 1988; Shippenberg et al.; 1993; but see Gerrits et al., 
1994), and there is also some evidence about the role of dopamine autorecep­
tors in opioid reinforcement (De Fonseca et al., 1995). Qne can find data, how­
ever, to indicate that the reinforcing actions of opioids may also involve dopa-
mine-independent mechanisms. In a study by Ettenberg et al. (1982), dopamin­
ergic antagonist a-flupentixol did not reduce the self-administration of heroin, 
but in doses that caused motor impairment; and similar effect (or rather, the 
lack of it) on the initiation of heroin self-administration has been observed with 
selective DI receptor antagonist SCH23390 (Gerrits et al., 1994). Furthermore, 
the study by Pettit et al. (1984) demonstrated that selective lesions of the do­
paminergic terminals in the nucleus accumbens significantly attenuated the 
self-administration of cocaine but not that of heroin. 
As far as the aversive properties of K opioids are concerned, again an in­
volvement of dopaminergic mechanisms has been suggested, K Receptors are 
present both in the VTA and its dopaminergic terminal fields in ventral striatum 
(nucleus accumbens), and the aforementioned structures are innervated by lat­
eral hypothalamic neurons containing K-agonistic opioid peptides, dynorphins 
(Mansour et al.\ 1988; 1995). Furthermore, the administration of K agonists, 
U50,488 and bremazocine, has been shown to cause a decrease in synaptic do­
pamine concentrations both in the caudate and nucleus accumbens (Di Chiara 
and Imperato, 1988). 
Dopaminergic substrate of cocaine reinforcement: Positive reinforcing 
properties of cocaine are dopamine-dependent as it has been demonstrated by 
several self-administration studies (e.g., Roberts et al., 1977; Caine and Koob, 
1995). Interestingly enough, both the neuroleptic drugs and the 6-hydroxydopa-
mine (6-OHDA) lesions of the nucleus accumbens have failed to influence con­
ditioned place preference induced by intraperitoneal cocaine (Morency et al., 
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1986, Spyraki et al, 1982). The effect of either intracerebroventricularly or 
intravenously administered cocaine was still blocked by pimozide (Morency et 
al., 1986) and haloperidol (Spyraki et al., 1987), respectively. In view of these 
data it has been questioned whether the effect of intraperitoneal cocaine truly 
reflects its central reinforcing properties, and alternative explanations have 
been proposed including local anaesthesic action of cocaine (Spyraki et al., 
1982). Drug discrimination studies (Colpaert et al, 1979), however, do not 
support the local anaesthesia hypothesis. Furthermore, according to the recent 
place conditioning study by Cervo and Samanin (1995), the effect of intraperi-
toneally administered cocaine was impaired by DI receptor antagonist 
SCH23390, and another study (Hemby et al., 1994) clearly demonstrates the 
predominant involvement of central components in place preference induced by 
intraperitoneal cocaine. 
Behavioral sensitization to opioids and the brain dopamine: The sensitizing 
effects of opioids are closely related to the reinforcing ones as the same neural 
substrate appears to be involved in both. However, as discussed above, the re­
lationship between behavioral sensitization and positive reinforcement is still 
somewhat problematic, and so is the role of dopamine in opioid reinforcement. 
Several lines of evidence suggest that the dopaminergic mechanisms underlie 
the behavioral sensitization to both opioids and psychomotor stimulants. With 
repeated administration, the aforementioned drugs become increasingly effec­
tive in activating the mesotelencephalic dopamine system (for review see Rob­
inson and Becker, 1986; Kaliwas and Stewart, 1991). Evidence suggests the 
involvement of independent neural substrates in the induction and expression of 
behavioral sensitization. Thus, the sensitization is induced by the administra­
tion of amphetamine and |.i-opioids to the region of dopamine cell bodies in the 
VTA but not to the nucleus accumbens, whereas the terminal fields (nucleus 
accumbens) are critical in its expression (Vezina et al, 1987; Cador et al, 
1995). The exact nature of the phenomenon is not fully understood. Beside the 
most consistent finding, i.e., the augmented mesoaccumbens dopamine release 
in response to psychomotor stimulant and (i-opioid challenge (Kaliwas and 
Stewart, 1991; Kaliwas et al., 1993), also changes in sensitivity of postsynaptic 
dopamine receptors have been detected. Concerning opioids, an enhancement 
of behavioral effects of dopamine receptor agonists have been observed both 
after acute morphine administration (Vedernikov, 1970; Martin and Takemori, 
1985; 1987) and during withdrawal from chronic treatment (e.g., Carlson and 
Almasi, 1979). The results are somewhat inconsistent, however. While most 
authors (e.g., Carlson and Almasi, 1979; De la Baume et al, 1979; Carlson and 
Seeger, 1982) found an enhancement of apomorphine-induced stereotypy, 
climbing, and locomotor activity during morphine withdrawal, some have failed 
to detect any changes (Kuschinsky, 1975). Furthermore, the issue is unclear 
with respect to the type of the dopamine receptor, because all of these studies 
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used apomorphine, which is an unselective dopamine receptor agonist (Seeman 
and Van Tol, 1994). 
2.5.3. Role of nitric oxide 
The free radical gas nitric oxide (NO) is an unconventional messenger mole­
cule. It is generated from the amino acid L-arginine by a family of enzymes, 
called NO synthases (Moncada et al., 1991). The function of NO in the central 
nervous system is widely related to excitatory amino acids, as in neurons it is 
formed in response to glutamate acting upon the NMDA receptor (Garthwaite 
et al., 1988). This process is catalyzed by the constitutive, neuronal isoform of 
NO synthase (Förstermann and Kleinert, 1995), and can be effectively sup­
pressed by the compounds that inhibit the enzyme. Yet, most such drugs are L-
arginine analogs that unselectively block also the other known NO synthases, 
the (constitutive) endothelial, and inducible isoforms, and have therefore re­
markable vascular effects (Moncada et al., 1991). Such circumstances make the 
interpretation of the results sometimes fairly complicated. There is, however, a 
novel group of inhibitors, 7-nitro indazole and related indazoles, which lack the 
capacity to elevate blood pressure. These compounds suppress the neuronal and 
inducible NO synthases, but in vivo apparently do not influence the activity of 
the endothelial isoform (Moore et al., 1993 a b; Wolff and Gribin, 1994). 
The release of NO is involved in many glutamate actions in the central 
nervous system, including cellular events that may underlie the processes of 
learning and memory (Schuman and Madison, 1991). Likewise, NO has been 
shown to regulate the release of neurotransmitters, dopamine included (Zhu and 
Luo, 1992). According to the results of recent studies NO may be implicated in 
the actions of opioids — so it has been demonstrated that the inhibitors of NO 
synthase could prevent morphine tolerance (Kolesnikov et al., 1992; Pasternak 
et al., 1995) and attenuate the development and expression of the abstinence 
syndrome (Kimes et al., 1993; Cappendijk et al., 1995). NO has been likewise 
shown to modulate morphine induced changes in locomotion and food intake in 
mice (Calignano et al., 1993), but hitherto there were no reports available re­
garding NO with relation to the positive reinforcing properties of opioids. 
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3. AIMS OF THE STUDY 
The present study was addressed to clarify the following questions: 
— Role of opioid receptors in positive reinforcing properties of morphine. 
Stress was laid upon the subtypes of the (I receptor and the 5 receptor. There­
fore we investigated the influence of the (il receptor antagonist naloxonazine 
and the 8 receptor antagonist naltrindole on place preference induced by mor­
phine. By way of comparison, the effect of unselective opioid antagonist 
naltrexone was studied. To evaluate the availability and selectivity of naloxo­
nazine, we also measured its effects on morphine-induced antinociception, hy­
perthermia, and catatonia (a state of immobilization that is regarded as a mix­
ture of muscle rigidity and akinesia). In rats catatonia is elicited by large doses 
of opioids (Ahtee and Kääriäinen, 1973) and has been shown to be mediated by 
the |0, receptor, particularly by the (0.1 subtype (Ling et al., 1986). As for mor-
phine-induced hyperthermia, it is readily antagonized by unselective opioid 
antagonist naloxone (Clark and Clark, 1980), but no data have been available 
concerning selective jLL opioid antagonists (see above about analgesia). 
— Role of brain dopamine in positive reinforcing properties of morphine 
with an emphasis on dopamine autoreceptors. The idea was that drugs that ac­
tivate dopamine autoreceptors, and hence decrease dopaminergic transmission, 
could interfere with morphine reinforcement. To test this hypothesis, we stud­
ied the influence of the two dopamine autoreceptor activating drugs, quinpirole 
and preclamol, on morphine- and (by way of comparison) cocaine-induced 
place preferences. Biochemical and behavioral investigations indicate that the 
selective D2/D3 receptor agonist quinpirole (LY171555) in small doses could 
act selectively at dopamine autoreceptors (White and Wang, 1986; Widzovsky 
and Gori-Slechta, 1993). Preclamol ([-]3PPP) is a partial dopamine autorecep­
tor agonist that also exhibits antagonistic properties at postsynaptic dopamine 
receptors (for review see Clark et al., 1985 a b). 
— Changes in sensitivity of dopamine D2/D3 receptors brought about by 
acute or repeated intermittent treatment with morphine. Therefore we investi­
gated the influence of acute morphine pretreatment and withdrawal from 
chronic morphine on quinpirole-induced yawning behavior, hypolocomotion, 
and stereotyped behavior in rats. 
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The yawning behavior is, however, a somewhat problematic model, because 
the location of the D2-like receptors that mediate yawning, is under discussion. 
While some authors have proposed that it may be mediated via presynaptic, i.e., 
autoreceptors (Protais et al., 1983), the others strongly suggest the postsynaptic 
location (Serra et al., 1986; Stähle, 1992). 
— Role of NO in positive reinforcing properties of morphine. With this 
purpose the influence of NO synthase inhibitor L-NOARG on morphine-in­
duced conditioned place preference was studied. In order to clarify the conse­
quences of mnemonic and motivational processes (see below), the effect of 
L-NOARG on K opioid agonist U50,488 induced place aversion was also in­
vestigated. 
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4. MATERIALS AND METHODS 
4.1. ANIMALS 
Male Wistar rats weighing 200-405 g were used. The rats were housed in 
groups of 4-6 with food and water available ad libitum, under 12 hours 
light/dark cycle (lights on at 6-7 a.m.). The experiments were carried out dur­
ing the light phase of the cycle. 
4.2. DRUGS 
The doses of morphine, naltrexone, and naloxonazine indicate the amount of 
the free base. Other doses refer to the salt. Morphine HCl (Ph. Eur. 2nd ed.) or 
morphine sulfate (ampoules containing 20 mg/ml of morphine sulfate; Antigen 
Pharmaceuticals LTD, Roscrea, Ireland), naltrexone HCl, and naloxone HCl 
(both Sigma Chemical Co., St. Louis, MO, USA), quinpirole HCl (LY17155; 
gift of Eli Lilly & Co, Indianapolis, Ind., USA), preclamol HCl ([-]3PPP; RBI, 
Natick, MO, USA, and gift of Suomen Astra OY), SCH23390 maleate [R-(+)-
8-chloro-2,3,4,-tetrahydro-3-methyl-5-phenyl-1 H-3-benzazepin-7-ol hemimale-
ate; gift of Schering Corp., Bloomfield, N.J., USA], and U50,488 (trans-(±)-
3,4-Dichloro-N-methyl-N-[2-(l-pyrrolidinyl)-cyclohexyl]-benzeneacetamide 
methanesulfonate; RBI, Natick, MO, USA) were administered SC into the neck 
region. Cocaine HCl (Ph. Eur. 2nd ed.) was injected IP. All the above named 
compounds were dissolved in 0.9% NaCl solution and given in a volume of 1-
2 ml/kg. Naltrindole (RBI Natick, MO, USA) was dissolved in 22.5% w/v so­
lution of 2-hydroxypropyl-ß-cyclodextrin and administered IP in a volume of 
2 ml/kg. Nalxonazine (RBI Natick, MO, USA) and NC0-nitro-L-arginine 
(L-NOARG; Sigma Chemical Co., St. Louis, MO, USA) were administered IP 
in a volume as above as 2.5% Tween® 80 solution. 
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4.3. CONDITIONED PLACE PREFERENCE 
The apparatus consisted of two square-base compartments (h 40 x 30 x 30 cm), 
one with white, and the other with gray walls and floor. Compartments were 
separated by a guillotine door and covered with a transparent Plexiglas ceiling. 
The apparatus was placed into a dimly lit room. 
Before starting the experiment the rats were acclimated to experimenter 
contact for three days by handling and weighing in the experiment room. The 
experiment consisted of three phases. 
Preconditioning. During three days (days 1, 2, and 3) rats were given free 
access to both compartments of the apparatus for 15 minutes each day. On day 
3, the time spent by rats in each compartment was recorded (the position of the 
rat was defined by the position of its front paws) and these values served as a 
baseline. According to the baseline values the animals were divided into treat­
ment groups with a similar initial preference. Since most of the rats preferred 
the gray compartment (i.e., they spent over 50% of time on that side), the ones 
preferring the white compartment were excluded from the experiment. 
Conditioning was conducted during four days (days 4, 5, 6, and 7) and in­
cluded two sessions each day. The rats were conditioned in the initially nonpre-
ferred chamber immediately after the administration of morphine or cocaine, 
and in the preferred one after the administration of saline (in control animals 
both compartments were paired with the injection of saline). An interval of four 
hours separated the two sessions. The order of drug (i.e., morphine or cocaine) 
and saline presentation, paired with the given environment, was balanced 
across treatment groups. Conditioning times of 45-60 and 45 min were used for 
morphine and cocaine, respectively. 
The doses of morphine (3 mg/kg SC) and cocaine (5 mg/kg IP) were se­
lected according to the previous studies (Bardo et al., 1995). Although there is 
no reliable dose-dependence with the doses of morphine above 1 mg/kg, the 
effect of this dose appears to be fairly unstable (Shippenberg and Herz, 1988; 
Bardo et al., 1995). For this reason, morphine was administered at 3 mg/kg. 
Opioid antagonists naltrexone (2.5 mg/kg SC), naloxonazine (15 mg/kg IP), 
and naltrindole (2 mg/kg IP) were administered 20 min, 12 hours, and 15 min 
prior to morphine administration, respectively. Quinpirole (0.05 mg/kg SC) was 
administered 5 and 10 min before morphine and cocaine, respectively. 
Preclamol (2 or 8 mg/kg) was given 15 minutes before morphine or cocaine 
administration, and L-NOARG (5 or 20 mg/kg IP) 15 minutes prior to morphine 
administration. In separate groups of rats the place conditioning effects of all 
the aforementioned pretreatment drugs were assessed. 
Postconditioning. The postconditioning test was carried out on day 8 (24 
hours after the last drug or vehicle administration). No injections were given 
prior to test. The rats had free choice in the apparatus for 15 minutes and the 
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time spent in each compartment was recorded by an observer unaware of the 
previous drug treatment. 
4.4. CONDITIONED PLACE AVERSION 
Conditioned place aversion experiments were carried out similarly to the place 
preference ones, with the exception that after the administration of U50,488 
(1 mg/kg SC) the rats were conditioned for 45 min in the initially preferred 
compartment. L-NOARG (20 mg/kg IP) was given 15 minutes prior to U50,488 
treatment. 
4.5. ANALGESIA AND RECTAL TEMPERATURE 
The pain sensitivity in rats was measured with the hot plate (Woolfe and Mac-
Donald, 1944). The animals were gently placed on a 55°C copper plate and as a 
latency period, the time to the onset of paw-licking movements was measured. 
Cutt-off time of 30 seconds was used. Naloxonazine (15 mg/kg IP) was given 
12 hours prior to morphine (3 mg/kg SC). Latencies were measured 30 and 
60 minutes after the administration of morphine. The antinociceptive effect was 
calculated as a percentage of maximum possible effect (% MPE): 
LTT- LTC 
%MPE = ^ x 100, 
CT-LTC 
where LTT = latency time of treated animals, LTC = latency before treatment, 
and CT = cut-off time. 
Rectal temperature was measured immediately prior to the hot-plate test by 
an electrical thermometer (Ellab, Copenhagen, Denmark) using a 4 cm long 
rectal probe. The animals were unrestrained during the measurements. 
4.6. CATATONIA 
Catatonia was measured every 30 min during 150 min after the administration 
of morphine (15 mg/kg SC). Four tests were used: 1) both front limbs of the rat 
were gently placed onto a 3 cm high horizontal bar; 2) both front limbs of the 
rat were placed onto a 9 cm high horizontal bar; 3) the front and hind limbs 
were placed onto parallel horizontal bars with a 6 cm distance between the 
bars; 4) the rat was placed on a metal grid positioned at an angle of 45°. Each 
24 
test was scored from 0 to 2: the score 1 was given if the animal remained im­
mobile for 10 seconds; the score 2 was given in case the animal remained im­
mobile for 20 seconds or more. The four tests were repeated five times during 
2.5h experiment; the scores were summed and taken as a measure of catatonia 
(maximum sum was 40). Naloxonazine (15 mg/kg IP) and naltrindole (2 mg/kg 
IP) were given 24 hours and 15 min after morphine administration, respec­
tively. 
4.7. CHRONIC MORPHINE TREATMENT 
Morphine was administered SC twice a day at 8.00 and 18.00 according to the 
schedule as follows: day 1: 10 and 10 mg/kg; day 2: 15 and 10 mg/kg; day 3: 15 
and 15 mg/kg; day 4: 20 and 15 mg/kg; day 5: 20 and 20 mg/kg; day 6: 25 and 
20 mg/kg; day 7: 25 and 25 mg/kg. On day 8 the animals were given morphine 
(30 mg/kg) in the morning only and placed back to their home cages for 
24 hours (this group is later referred to as morphine withdrawn animals. A 
separate group of animals was given saline repeatedly. 
4.8. LOCOMOTOR ACTIVITY 
Locomotor activity was measured in a microcomputer-controlled photocell ac­
tivity monitor, which contained 5 Plexiglas activity boxes of 31 x 21 x 20 cm 
(one rat per box). Locomotor activity was monitored either every 30 min during 
180 min after the acute administration of morphine (3 mg/kg SC), or, in the 
case of chronic morphine treatment, 24 hours after the last morphine admini­
stration every 5 min over a 20 min period after quinpirole (0.025 mg/kg SC) 
administration. The rats had no previous experience with the activity box. 
4.9. YAWNING BEHAVIOR 
The rats were placed into individual Plexiglas boxes (31 x 21 x 20 cm) imme­
diately after the administration of quinpirole (0.01-1 mg/kg SC) and the num­
ber of yawning episodes was recorded during 30 rnin. In the case of chronic 
morphine treatment yawning was assessed 24 hours after the last morphine ad­
ministration. 
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4.10. STEREOTYPY 
The intensity of stereotypy was rated according to a four-point severity scale by 
two independent observers for 60 min after quinpirole (1 mg/kg SC) admini­
stration. The scoring system was as follows: 0 — no stereotypy; 1 — periodic 
sniffing with some locomotion; 2 — continuos sniffing; 3 — periodic biting, 
gnawing, or licking; 4— continuos (1 min) biting, gnawing, or licking, no lo­
comotion (Costall etal. 1977). 
4.11. STATISTICS 
The data of place conditioning experiments were subjected to two-factor analy­
sis of covariance (ANCOVA), where the time spent in the drug-paired com­
partment during the postconditioning test served as a dependent variable, drug 
treatments as categorical variables, and the baseline as covariate. Where neces­
sary, the post-hoc comparisons were conducted by using either the Tukey-
compromise test or the contrast analysis with Bonferroni levels (i.e., the critical 
level 0.05 was divided by the number of the comparisons made). 
Data from the hot-plate test were analyzed either with the Wilcoxon test 
(effects of acute drug) or the Mann-Whitney U-test (effects of pretreatment). 
Catatonia scores were compared with the Mann-Whitney U-test; rectal tem­
peratures were compared with the paired t-test. 
Locomotor activity data were analyzed with the unpaired t-test, or with re­
peated measures ANOVA, followed by the contrast analysis where necessary. 
The data on yawning behavior were subjected to ANOVA or the Kruskall-
Wallis test; the post-hoc comparisons were conducted with either the Newman-
Keuls test or the Mann-Whitney U-test, respectively. 
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5. RESULTS 
5.1. OPIOID RECEPTORS 
5.1.1. Effect of opioid receptor antagonists on morphine-induced 
place preference 
Results are shown in Fig. 1 (panels A, B, and C). In all experiments morphine 
induced significant place preference [morphine factor, F(l,47) = 5.18, p = 
0.028; F(l,49) = 12.56, p = 0.0009; and F(l,28) = 23.66, p < 0.001; for the ex­
periments with unselective opioid antagonist naltrexone, |il receptor antagonist 
naloxonazine, and 5 receptor antagonist naltrindole, respectively]. Likewise, 
significant morphine x naltrexone and morphine x naloxonazine interactions 
[F( 1,47) = 10.65, p = 0.002; and F(l,49)= 6.88, p = 0.002; respectively] were 
established, and further multiple comparison revealed that the effect of mor­
phine was significantly antagonized by naltrexone and naloxonazine. Naltrex­
one and naloxonazine by themselves did not induce any significant place con­
ditioning. Naltrindole had neither significant place conditioning effect by itself, 
nor did it influence the effect of morphine. 
Taken together, morphine-induced place preference was significantly attenu­
ated by unselective opioid antagonist naltrexone and |il receptor antagonist 
naloxonazine, whereas 8 receptor antagonist naltrindole failed to show any reli­
able effect. 
5.1.2. Effect of opioid receptor antagonists on morphine-induced 
catatonic state, antinociceptoin, and hyperthermia 
Morphine (15 mg/kg, SC) produced a marked catatonic effect, which lasted for 
about 120 min. This catatonia was significantly antagonized by naloxonazine 
(U = 13.5, p = 0.017 as compared vehicle pretreatment, Mann-Whitney U-test) 
but not by naltrindole. 
Naloxonazine clearly antagonized morphine-induced antinociception (Ta­
ble 1). Morphine induced significant increase in rectal temperature at 30 and 
60 min after its administration. Naloxonazine had no reliable influence on this 
effect (Table 1). 
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• PRECONDITIONING 
j POSTCONDITIONING 
SAL + SAL SAL + MO NTX + SAL NTX + MO 
VEH + SAL VEH + MO NAZ + SAL NAZ + MO 
c 
500-
200-
VEH+SAL VEH + MO NTI + SAL NTI + MO 
Figure 1. Effect of unselective opioid antagonists naltrexone (2.5 mg/kg SC, panel A), 
jil receptor antagonist naloxonazine (15 mg/kg IP, panel B), and 8 receptor 
antagonist naltrindole (2 mg/kg IP) on place preference induced by morphine 
(3 mg/kg SC). The columns depict the mean (± SE) time, the rats (n = 7-18) 
spent in the initially nonpreferred (i.e., drug-paired) compartment during pre-
and postconditioning tests. Abbreviations: SAL — saline, VEH — vehicle, 
MO — morphine, NTX — naltrexone, NAZ — naloxonazine, NTI — nal­
trindole. * p < 0.05, ** p < 0.01 vs. control (SAL + SAL or VEH + SAL) 
group. ° p < 0.05;00 p < 0.01 vs. morphine group (Tukey-compromise test). 
28 
T a b l e  1  
The effect of naloxonazine pretreatment (15mg/kg, IP, 12 h) on morphine-induced 
(3 mg/kg, SC) antinociception and hyperthermia. Antinociception was measured by es­
timating the latency (s) and mean percentage of maximum possible effect (% MPE). The 
rectal temperatures (Trect, °C) were measured in the same animals immediately before 
placing them on the hot plate. The median values ±95% confidence limits (latency and 
%MPE) or the mean values ± SE (Trect, °C) of 7-8 animals are given. 
Time after morphine administration 
Pretreatment 0 min 30 min 60 min 
Latency 
Vehicle 8.4±2.9 16.2±3.2 * 9.4±1.4 
Naloxonazine 12.8±3.3 12.3±3.0 10.0±2.9 
% MPE 
Vehicle 31.6±15.1 0.5±14.4 
Naloxonazine -12.2±26.1# -2.6±23.2 
Trect °C 
Vehicle 38.0±0.1 38.6±0.2 * 38.7±0.2 * 
Naloxonazine 38.3±0.1 38.9±0.1 * 38.9±0.2 * 
* p < 0.05 vs. corresponding value at 0 min, Wilcoxon test (latency and % MPE) or 
paired t-test (Trect, °C). # p < 0.05 vs. vehicle pretreatment; Mann-Whitney U-test. 
5.2. DOPAMINE RECEPTORS 
5.2.1. Effect of quinpirole and preclamol on place preference induced 
by morphine and cocaine 
Dopamine D2/D3 receptor agonist quinpirole (0.05 mg/kg) or dopamine autore-
ceptor agonist preclamol (2 or 8 mg/kg) by themselves had no significant place 
conditioning effect (Fig. 2 panel A). 
Morphine induced significant place preference [F(l,67) = 14.56, p< 0.01]; 
neither quinpirole nor preclamol (8 mg/kg) had any significant influence on this 
effect (Fig. 2 panel C). 
Likewise, cocaine brought about significant place preference [F(l ,69) = 
18.9, p < 0.01]. This effect was significantly impaired by 8 mg/kg of preclamol 
but was unaffected by quinpirole and preclamol at the dose 2 mg/kg (Fig. 2 
panel B). In fact, ANCOVA revealed a nonsignificant quinpirole X cocaine 
interaction [F( 1,69) = 0.44, p = 0.5], while the preclamol X cocaine interac­
tion was significant [F(2,70) = 5.1, p = 0.009]. Two planned post-hoc compari-
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I I Preconditioning 
HI Postconditioning 
P sal Q P2 P8 
(34) (10) (6) (7) 
SALINE 
(15) (15) (8) (7) 
COCAINE 
MORPHINE 
Figure 2. Effect of quinpirole and preclamol on conditioned place preference induced 
by morphine or cocaine in rats. Panel A: the effect of quinpirole and 
preclamol in saline treated control rats. Panel B: the effect of drugs on place 
preference induced by cocaine (5 mg/kg IP). Panel C: the effect of drugs on 
place preference induced by morphine (3 mg/kg SC). The columns depict the 
mean (± SE) time, spent in the initially nonpreferred (i.e., drug-paired) com­
partment during pre- and postconditioning tests. Abbreviations under columns 
indicate the pretreatment during conditioning: sal — saline, Q —- quinpirole 
(0.05 mg/kg SC), P2 — preclamol (2 mg/kg SC), P8 — preclamol (8 mg/kg 
SC). Number of animals in brackets. # p < 0.01 compared with control (sa­
line + saline) group; * p < 0.05 compared with saline-pretreated cocaine 
group (contrast analysis with Bonferroni adjustment). 
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sons (contrast analysis) revealed no significant difference between the treat­
ment groups preclamol 2 mg/kg + cocaine and saline + cocaine, whereas the 
difference between the groups preclamol 8 mg/kg + cocaine and saline + co­
caine was significant [F(l,70)= 6.45, p= 0.013, which is below the corre­
sponding critical p value 0.025 for two comparisons]. 
5.2.2. Effect of acute morphine administration on quinpirole-induced 
yawning in rats 
Quinpirole, over a wide dose-range (0.01-0.1 mg/kg SC), induced yawning be­
havior with maximum effects occurring at doses 0.05 and 0.1 mg/kg SC. Fur­
ther increase in the dose of quinpirole brought about a decrease in yawning and 
the appearance of low intensity stereotyped behavior. 
The effect of morphine (3 mg/kg SC) on quinpirole induced yawning be­
havior was dependent on the pretreatment interval. Morphine, given 15 min 
prior to quinpirole (0.1 mg/kg SC), nearly totally inhibited yawning, and a sig­
nificant reduction was also present when morphine was administered 60 min 
prior to quinpirole. In the case of pretreatment intervals of 90 and 120 min, 
there was no significant differences in yawning between the morphine-
pretreated and control groups. 
5.2.3. Effect of naloxone on quinpirole-induced yawning 
in morphine-pretreated rats 
Naloxone, given 1 mg/kg 10 min before quinpirole (0.1 mg/kg SC), had no sig­
nificant influence on yawning in control rats, yet it restored the yawning be­
havior that was inhibited by 15 min morphine pretreatment. In contrast, 
naloxone further reduced the yawning behavior in rats that received morphine 
as a 90 min pretreatment. When administered to rats that received morphine 
150 min before quinpirole, naloxone had no significant effect. 
5.2.4. Effect of SCH23390 on quinpirole-induced yawning 
in morphine pretreated rats 
D1 receptor antagonist SCH23390 given at 0.01 mg/kg SC did not affect the 
quinpirole-induced yawning by itself. Nor did it reliably influence yawning be­
havior in the rats that were administered morphine 15 min prior to quinpirole. 
However, in the case of 90 min morphine pretreatment, SCH23390 clearly en­
hanced the quinpirole-induced yawning. 
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5.2.5. Effect of morphine withdrawal on quinpirole-induced yawning 
behavior in rats 
Results are shown in Fig. 3. The occurrence of yawning episodes followed an 
inverted U-shaped curve with the maximum effect at 0.01-0.1 mg/kg. Morphine 
withdrawal significantly enhanced yawning induced by 0.01 and 0.1 mg/kg of 
quinpirole. Quinpirole, given at 1 mg/kg, caused significantly less yawning in 
morphine-withdrawn rats than in controls. 
j I Control jHH Morphine withdrawal 
0.01 0.1 
Quinpirole (mg/kg) 
Figure 3. Quinpirole-induced yawning in morphine-withdrawn rats. The columns depict 
the mean (± SE), n = 8-10 animals. *p < 0.05; **p < 0.01 as compared to 
corresponding control group (Mann-Whitney U-test). 
5.2.6. Effect of acute morphine treatment and morphine withdrawal 
on locomotor activity in rats. Influence of morphine withdrawal on 
quinpirole-induced hypolocomotion 
Acute administration of morphine (3.0 mg/kg SC) exhibited a clear biphasic 
effect on locomotor activity. An initial phase of immobility that persisted up to 
30 min, was turned into a significant increase in activity. The phase of loco­
motor activation started about 60 min after morphine administration, lasted for 
about 60 min, and returned to the control level within 150-180 min after mor­
phine administration. 
Both quinpirole (0.025 mg/kg SC) and withdrawal from chronic morphine 
treatment significantly suppressed locomotor activity [F(l,28) = 10.5, p < 0.01; 
and F(l,28) = 10.0, p < 0.01, respectively]. In fact, ANOVA revealed also sig­
nificant effects for quinpirole X morphine withdrawal interaction [F(l,28) = 
6.8, p < 0.05], indicating that morphine withdrawal further potentiated the in­
hibitory effect of quinpirole. However, this could not be revealed by post-hoc 
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comparisons. Within subject analysis revealed that it was only the effect of 
quinpirole that was significantly dependent on time [F(3,84) = 7.5, p < 0. 05]. 
5.2.7. Effect of morphine withdrawal on quinpirole-induced 
stereotyped behavior in rats 
In the control rats quinpirole, given at 1 mg/kg induced stereotypy of low inten­
sity as indicated by the sniffing episodes. No licking or gnawing could be ob­
served in these animals. Withdrawal from repeated morphine treatment resulted 
in an enhancement of quinpirole-induced stereotypy. In these rats the stereo­
typed response was expressed not only by intense sniffing but also by the ap­
pearance of licking and occasional gnawing. 
5.3. NITRIC OXIDE 
5.3.1. Effect of NO synthase inhibitor L-NOARG 
on morphine-induced place preference 
Results are shown in Fig. 4 panel A. ANCOVA revealed a significant effect for 
the morphine factor [F(l,44) = 13.5, p= 0.001] indicating that morphine 
brought about reliable place preference. In addition, a significant effect 
[F(2,44) = 3.2, p = 0.049] was established for L-NOARG and a nearly signifi­
cant one for the L-NOARG x morphine interaction [F(2,44) = 2.9, p = 0.066]. 
In order to further clarify the nature of these effects, four post-hoc comparisons 
were conducted: the treatment groups L-NOARG 5 mg/kg + saline and 
L-NOARG 20 mg/kg + saline were tested against the group vehicle + saline, 
whereas the groups L-NOARG 5 mg/kg + morphine and L-NOARG 20 mg/kg + 
morphine against the group vehicle + morphine. In most cases no significant 
differences were found [F(l,44) = 0.02-0.5; p = 0.48-0.88]. However, for the 
comparison L-NOARG 20 mg/kg + morphine vs. vehicle + morphine the con­
trast analysis revealed F(l,44) = 11.6, p = 0.001. This can be considered sig­
nificant because it is well below the corresponding critical p value 0.0125 for 
four comparisons. Thus, L-NOARG when given at 20 mg/kg reliably attenuated 
the effect of morphine. 
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5.3.2. Effect of NO synthase inhibitor L-NOARG on U50,488-
induced place aversion 
Results are shown in Fig. 4 panel B. K Receptor agonist U50,488 (1 mg/kg SC) 
induced significant place aversion [F(l,32)= 14.13, p= 0.001]. ANCOVA 
likewise revealed no significance for the factor L-NOARG and L-NOARG x 
U50,488 interaction. Hence, L-NOARG neither induced any place conditioning 
by itself, nor did it influence the effect of U50,488. 
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Figure 4. Effect of NO synthase inhibitor L-NOARG on place preference induced by 
morphine (3 mg/kg SC, panel A), and place aversion, induced by K opioid re­
ceptor agonist U50,488 (1 mg/kg SC, panel B). The columns depict the mean 
(± SE) time, spent in the drug-paired compartment (initially nonpreferred or 
preferred, for panels A and B, respectively) during pre- and postconditioning 
tests. Number of animals in brackets. Abbreviations: sal — saline, veh — ve­
hicle, Mo — morphine, N5 — L-NOARG 5 mg/kg IP, N20 — L-NOARG 
20 mg/kg IP, U — U50,488. * — p < 0.05 compared with the group veh + 
Mo (contrast analysis with Bonferroni adjustment). 
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6. DISCUSSION 
6.1. ROLE Of OPIOID RECEPTOR SUBTYPES IN POSITIVE 
REINFORCING PROPERTIES OF MORPHINE 
In our experiments morphine, given 3 mg/kg SC, induced reliable place prefer­
ence in rats, which well agrees with the numerous previous findings. Thus, 
morphine has been shown to produce such an effect over its entire usable dose 
range, from a small dose of 0.08 mg/kg (IV) to the doses sublethal for opioid 
naive rats (10-15 mg/kg, IV; for discussion see van der Kooy, 1987; Bardo et 
al., 1995). On the other hand, a small dose (0.05 mg/kg) of morphine, but only 
when administered intraperitoneally, has been shown to elicit place aversion 
(Bechara and van der Kooy, 1985; 1987). 
Morphine-induced place preference was significantly antagonized by the 
unselective opioid antagonist naltrexone, and the selective |il opioid antagonist 
naloxonazine. Hence, our results indicate a critical role of the (0,1 receptor in 
positive reinforcing properties of morphine. The involvement of the \i2 receptor 
remains unclear, since no selective antagonist is available as yet. 
Unlike the rats, in mice the blockade of JLX 1 receptors by naloxonazine did 
not affect morphine-induced place preference (Suzuki et al., 1993). This could 
be explained by the fact that mice differ from rats in many respects, including 
the distribution and proportion of opioid receptors in various areas of the brain 
(Goodman and Pasternak, 1985; Goodman et al., 1988; Waksman et al., 1986; 
Mansour et al., 1988). Rats and mice also differ in their behavioral responses to 
morphine, for large doses of morphine induce catatonia in rats (JLI 1 -effect) but 
locomotor activation in mice (Kuschinsky and Hornykiewicz, 1974; Saito 
1989). 
Naloxonazine is an azine derivative of naloxone, and its reversible action 
closely resembles that of naloxone in binding studies (i.e., it binds all types of 
opioid receptors; Hahn et al., 1985). Only irreversible binding of naloxonazine 
has been shown to be JLI 1 -selective, and under in vivo conditions the best pi 1-
selectivity is reached when the drug is given about 24 hours before agonist 
(Ling et al., 1986). In our place conditioning experiments, naloxonazine was 
administered 12 h before morphine (this was done for methodological reasons 
in order to prevent overlapping with conditioning sessions). One may argue that 
at this time point (i.e., 12 h after morphine administration) naloxonazine may 
have had affinity to other opioid receptors than the (u 1 subtype. However, the 
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fact that naloxonazine was unable to antagonize morphine-induced hyperther­
mia, an effect that is readily antagonized by the unselective antagonist naloxone 
(for an extensive review see Clark and Clark 1980), indicates that naloxonazine 
acted selectively at the (il site. 
Our conclusion is likewise supported by earlier studies. The (il receptor 
subtype has been shown to be involved in natural rewards as feeding (Mann et. 
al., 1988 a b; Simone et al., 1985), drinking (Mann et al., 1988 a; Simone et al., 
1985), and maternal behavior (Mann et al., 1990). Moreover, rats readily self-
administer orally etonitazene (Caroll et al., 1979), an opioid agonist that is 
rather selective for the JLLI receptor (Moolten et al., 1993). Etonitazene also in­
duces place preference (Sala et al., 1992). Therefore, it appears likely that al­
though the |ll selective analgesics would lack some undesirable side effects as 
the respiratory depression and inhibition of gastrointestinal transit, they can 
serve as positive reinforcers and cause addiction. 
Though morphine is regarded as a (J,-opioid, it has some affinity to the 8 re­
ceptors as well (Corbett et al, 1993). 8 Receptors predominate over the jl type 
in the nucleus accumbens (Goodman et al., 1983; Mansour et al., 1988), and 
have been proposed to mediate reinforcing effects produced by intra-accumbal 
morphine (Shippenberg et al., 1993). Significant commitment of 5 receptors has 
been likewise shown in cocaine reinforcement (Menkens et al, 1992). There­
fore, the 5 receptors could well mediate a part of reinforcing effects of systemi-
cally administered morphine. Our results, however, do not support this idea, 
because naltrindole was without any effect on morphine-induced place prefer­
ence. Nor did the intracerebral administration of 8 receptor antagonist ICI 
174,864, modify the place preference induced by morphine administered ICV 
(Shippenberg et al., 1987). Furthermore, naltrindole affected the self-admini­
stration of heroin only in doses 10 and 15 mg/kg (Negus et al., 1993), which 
were 10-1000 times larger than the ones needed to antagonize the antinocicep­
tion induced by the selective 8 receptor agonists DPDPE and DSLET (Crook et 
al. 1992). Considering that naltrindole blocks both putative subtypes (i.e., 81 
and 82) of 8 receptors (Pasternak, 1993; Traynor and Elliott, 1993), the in­
volvement of 8 receptors in morphine reinforcement seems unlikely. 
6.2. ROLE OF BRAIN DOPAMINE IN MORPHINE AND 
COCAINE REINFORCEMENT 
In the present study both the dopamine D2/D3 receptor agonist quinpirole, and 
the partial dopamine autoreceptor agonist preclamol failed to reliably affect 
morphine-induced place preference. The effect of cocaine was not influenced 
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by quinpirole, whereas it was significantly attenuated by relatively high dose of 
preclamol. 
A self-administration study by Caine and Koob (1993) demonstrated that the 
dopamine D2/D3 receptor agonists quinpirole and 7-hydroxy-(2-N,N-dipropy-
lamino)-tetraline (7-OH-DPAT), when co-administered with cocaine (at doses 
that were not self-administered by themselves), reduced cocaine intake by in­
creasing the intervals between injections without disrupting self-administration. 
The same effect occurs when the dose of cocaine is increased (Yokel, 1987). 
The authors suggested that "... D3 selective dopamine agonists may interact 
presynaptically to enhance cocaine's reinforcing properties". In another study 
the administration of 7-OH-DPAT inhibited both the expression and the acqui­
sition of morphine-induced place preference (De Fonseca et al., 1995). The re­
sults of our study do not agree with either of these works, for the effect of 
preclamol was antagonistic to cocaine, and neither preclamol nor quinpirole 
significantly influenced the effect of morphine. Moreover, according to our re­
sults it appears that the activation of dopamine autoreceptors was not sufficient 
to antagonize positive reinforcing properties of cocaine. Thus, cocaine-induced 
place conditioning was inhibited by the higher dose of preclamol, whereas the 
smaller dose of preclamol that has been shown to activate the autoreceptors 
(Arnt, 1983), and quinpirole were ineffective. Quinpirole, acting upon dopa­
mine autoreceptors, reduces the release of dopamine both in vivo (See et al., 
1991) and in vitro (Bull and Sheenan, 1991), yet, it does not block it entirely. It 
has been shown, furthermore, that only extensive lesions (> 90%) with 
6-OHDA could effectively reduce psychomotor stimulant reward (Roberts et 
al., 1977, Roberts et al., 1979). Martin-Iverson et al. (1985) proceeding from 
their work with indirect dopaminergic agonists, methylphenidate and nomifens­
ine, proposed that "... even a slight increase in activation of DA (dopamine) 
receptors could be sufficient to produce a rewarding effect". Such an explana­
tion also seems to be appropriate in our case, in order to interpret the lack of 
quinpirole's effect. Preclamol, besides being a partial dopamine autoreceptor 
agonist, has antagonistic properties upon postsynaptic dopamine receptors 
(Clark et al., 1985a b). Therefore, the effect of the larger dose of preclamol 
could be due to either its postsynaptic or the combination of its pre- and post­
synaptic actions. 
Concerning cocaine, one of the reasons for the inconsistency in our vs. 
Caine and Koob's (1993) results could be the difference in paradigms used: 
intravenous self-administration vs. conditioned place preference. As far as in­
travenous self-administration is concerned the animals are tested under the di­
rect influence of drugs (that is not the case in place conditioning). Thus, besides 
the changes in reinforcing effects, the changes in motor behavior may serve as 
an underlying cause: a decrease or increase in the response rate may result from 
an inhibition or stimulation of motor behavior, respectively (Yokel, R. A. 
1987). Since both 7-OH-DPAT and quinpirole in "autoreceptor selective" doses 
io 37 
reduce locomotor activity (Daly, et al., 1993; Jackson, et al., 1989), their direct 
influence on test performance may serve as a confounding factor. According to 
a later study, however, the pretreatment with 7-OH-DPAT does appear to spe­
cifically enhance the reinforcing properties of cocaine (Caine and Koob, 1995). 
Yet, in this event the same research would rather refer to the involvement of 
postsynaptic D2/D3 receptors than dopamine autoreceptors. 
As to morphine, its place conditioning effect was unaltered both by quinpi­
role and preclamol in our study, whereas it was attenuated by 7-OH-DPAT (De 
Fonseca et al. 1995). This attenuation could be brought about by 7-OH-DPAT 
inhibiting the mesolimbic dopamine, provided that this system is critical in 
opioid reinforcement. As the authors note, however, there are alternative expla­
nations available, including the disruption of attentional functions necessary for 
place conditioning to develop. In fact, the acquisition of morphine-induced 
place preference was attenuated by relatively high doses (0.25 and 5 mg/kg) of 
7-OH-DPAT that could elicit disorganized behavior (De Fonseca et ai, 1995). 
The central role of the dopaminergic substrate in positive reinforcing prop­
erties of opioids is referred to by a substantial body of evidence (Bozarth and 
Wise, 1981; Smith et al., 1985; Spyraki et al., 1982). A place conditioning 
study by Shippenberg et al. (1993) suggests the significance of the D1 receptor 
in the nucleus accumbens (but see below, Gerrits et al., 1994). It has been also 
demonstrated that selective D1 receptor antagonist SCH23390, over a large 
dose range increases the responding for heroin, which was interpreted as a de­
crease in heroin reinforcement (Nakajima and Wise, 1987). On the other hand, 
several studies do not agree with such a dopaminergic hypothesis (e.g., Etten-
berg et al., 1982; Mackey and van der Kooy, 1985; Pettit et al., 1984). Dopa­
mine receptor antagonist, alpha-flupentixol, while eliminating intravenous self-
administration of cocaine, did not reduce self-administration of heroin unless 
given in doses that impaired locomotor activity (Ettenberg et al., 1982). Neither 
did small doses of alpha-flupentixol cause a compensatory increase in re­
sponding for heroin (Ettenberg et al., 1982). Likewise, SCH23390, when given 
systemically, affected the initiation of heroin self-administration only in doses 
that inhibited motor behavior as well, and lacked the effect in the case of local 
administration in the nucleus accumbens (Gerrits et al., 1994). In our study 
preclamol at the dose that impaired the cocaine place conditioning, had no sig­
nificant effect on place preference induced by morphine. Our data thus agree 
with the earlier reports indicating the dopamine-independent components in 
positive reinforcing effects of opioids. 
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6.3. DOPAMINE D2/D3 RECEPTORS AND MORPHINE-
INDUCED BEHAVIORAL SENSITIZATION 
In accordance with previous studies (Babbini and Davis, 1972; Smee and Over-
street, 1976; Gen9 et al., 1983), acute administration of morphine (3 mg/kg) 
produced a biphasic effect on locomotor activity. An initial phase of inhibition, 
lasting for about 30 min, was followed by stimulated locomotor activity over 
about a 60 min period. The phase of morphine-induced hypoactivity was ac­
companied by a decrease in quinpirole-induced yawning. A similar effect of 
morphine on apomorphine-induced yawning has been described previously by 
Berendsen and Gower (1986). The fact that naloxone reversed this inhibitory 
action refers to the involvement of opioid receptors. 
During the phase of locomotor stimulation the yawning behavior in mor­
phine-treated rats was similar to the quinpirole controls. In view of the fact that 
D1 receptor antagonist strongly enhanced yawning in morphine-treated rats (but 
not in controls) suggests an increase in the sensitivity of D2/D3 receptors. 
Thus, morphine-induced locomotor activation is dependent on the activity of 
D1 receptors, for it is specifically inhibited by D1 receptor antagonist 
SCH23390 (Longoni et al., 1987). On the other hand, it has been shown that the 
activation of D1 receptors by the selective agonist SKF38393 suppresses apo-
morphine-induced yawning, and this effect is can be reversed by SCH23390 
(Zharkovsky and Cereska, 1989). Hence, the blockade of D1 receptor during 
the morphine-induced locomotor activation removed the inhibitory influence of 
the activated D1 receptors, and therefore the effect of quinpirole-activated su­
persensitive D2/D3 receptors could manifest itself. 
Likewise, withdrawal from repeated morphine administration appeared to 
enhance the sensitivity of D2/D3 receptors. In morphine withdrawn rats an en­
hancement of yawning behavior could be observed after small doses (0.01 and 
0.1 mg/kg) of quinpirole, whereas in the case of a large dose (1 mg/kg) the 
yawning response was reduced in comparison with controls. This could be ex­
plained by the occurrence of the stereotyped behavior in morphine withdrawn 
rats, for as shown by Protais et al. (1983), the stereotypies and yawning behav­
ior are mutually exclusive. The increased score of the stereotyped behavior in 
morphine withdrawn rats was due to the appearance of the high-degree stereo­
typy, licking and gnawing, which were not seen in control rats. This was rather 
unexpected because previous studies have revealed the requirement of con­
comitant activation of D1 receptors for high degree stereotypy to occur 
(Dall'Ollio et al., 1988;Vasse et al., 1988). 
Both withdrawal from repeated morphine and the administration of quinpi­
role clearly reduced locomotor activity. It appears, however, that in morphine-
withdrawn rats the locomotor activity was already nearly maximally inhibited, 
and therefore any further reduction by quinpirole could hardly be detected. The 
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locomotor activity test thus proved to be fairly insensitive in our experimental 
conditions. 
Taken together, both acute morphine administration and withdrawal from 
repeated morphine treatment induced the supersensitivity of D2-like receptors 
that mediate yawning behavior. The significance of the latter with respect to 
morphine as a positive reinforcer remains, however, an unresolved question. It 
is especially so if one has in mind the results of the present study, which do not 
refer to any significant involvement of these receptors in morphine reinforce­
ment (see above). 
T a b l e  2  
Manipulations influencing opioidergic, dopaminergic, and NMDA / NO circuits in the 
central nervous system — their impact on positive reinforcing properties of fi-opioids 
(morphine or heroin). The table does not include some studies that contradict the present 
research (these have been discussed in the text) 
Manipulation Effect on (i-opioid 
reinforcement 
References 
Opioid receptors 
Blockade of fil receptors attenuation Present study 
Blockade of 8 receptors no effect Present study 
Shippenberg et al., 1987 
Dopamine 
Blockade of D1 receptors inconclusive data Shippenberg and Herz, 1988; 
Shippenberg et al., 1993 
Gerrits et al, 1994 
Blockade of (postsynaptic) 
D2 receptors inconclusive data Leone and Di Chiara, 1987 
Activation of dopamine au­
toreceptors no effect 
Shippenberg and Herz, 1988; 
Shippenberg etal., 1993 
Present study 
Lesions of the nucleus ac­
cumbens no effect Pettit et al., 1984 
NMDA / NO cascade 
Blockade of NMDA recep­
tors 
NO synthesis inhibition 
attenuation 
attenuation 
Tzschentke and Schmidt, 1995 
Present study 
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6.4. ROLE OF NITRIC OXIDE IN POSITIVE REINFORCING 
PROPERTIES OF MORPHINE 
The effect of morphine was significantly attenuated by NO synthase inhibitor 
L-NOARG given at 20 mg/kg intraperitoneal^. L-NOARG itself had no reli­
able place conditioning effect. 
Apparently the L-NOARG's influence on morphine place conditioning was 
not due to some of its aversive properties because it failed to elicit any place 
aversion, regardless whether paired with the preferred or nonpreferred side. 
Nevertheless, the nature of L-NOARG's effect is a rather perplexing question, 
because several processes may be underlying. The acquisition of place prefer­
ence involves thus both mnemonic and motivational components, which can be 
manipulated separately (White and Carr, 1985). Since NO is involved in long-
term potentiation (Schuman and Madison, 1991), L-NOARG may have im­
paired the acquisition of place preference due to its impact on mnemonic proc­
esses rather than interference with motivational properties of morphine. The 
role of NO in different forms of learning and memory, however, is somewhat 
problematic. In the study by Böhme et. al. (1993) L-NOARG in the dose 25 
mg/kg IP (i.e., similar to the one effective in the present study) given over four 
days, was ineffective both in impairing radial maze learning in rats and block­
ing LTP in ex vivo prepared hippocampal slices. Yet the same dose almost to­
tally inhibits the brain NO synthase activity (Salter and Duffy, 1995). This sug­
gests that the observed inhibition of morphine-induced place preference cannot 
be explained solely by the impairment of mnemonic processes, and hence, our 
finding may have been based on the changes of motivational origin. Moreover, 
in our study L-NOARG (20 mg/kg IP) failed to affect the U50,488-induced 
place aversion, which it could have done provided that the target for L-NOARG 
was the mnemonic component of place conditioning. This fact also offers some 
rationale to propose the motivational changes in the case of morphine 
(however, we cannot exclude the possibility that the mechanisms mediating the 
mnemonic processes in place conditioning with morphine and U50,488, do not 
coincide). On the other hand, it shows that NO is not involved in the aversive 
properties of K opioids. 
Evidence suggests that NO may participate in the modulation of dopaminer­
gic neurotransmission, for NO release-inducing agents sodium nitroprusside 
and L-arginine have been shown to enhance the release of dopamine in striatal 
slices (Zhu and Luo, 1992). However, as far as the reinforcement process is 
concerned, the available data are rather equivocal. The inhibition of NO syn­
thesis attenuated cocaine-induced dopaminergic behaviors in mice, place pref­
erence included (Kim and Park, 1995). On the other hand, in rats it failed to 
affect both dopamine-dependent lateral hypothalamic brain stimulation reward, 
and the ability of cocaine to lower reward thresholds for electrical brain stimu-
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lation (Bozarth et al., 1994). As discussed above, the role of dopamine in 
opioid reinforcement is, in fact, a fairly obscure question. Hence, supposing 
that there is no commitment of NO in the dopamine related reinforcement proc­
ess in rats, it is possible that NO is involved in the dopamine-independent 
mechanisms of opioid reinforcement. 
In the brain NO is akin to glutamate (Garthwaite et al., 1988), and with con­
siderations as above it is tempting to speculate about the glutamate's commit­
ment in positive reinforcing effects of morphine. Thus, NMDA receptor an­
tagonists have been shown to inhibit morphine-induced place preference 
(Tzschentke and Schmidt, 1995), which the authors proposed to result from the 
disruption of associative learning, or the interference with dopaminergic proc­
esses in the brain. Such an explanation is strongly sustained by the involvement 
of glutamate in cellular plasticity processes (Collingridge and Singer, 1990). 
Moreover, the activity of the mesotelencephalic dopaminergic transmission is 
regulated via afferent glutamatergic projections from the prefrontal cortex to 
the VTA (Gariano and Groves, 1988), and from hippocampus, amygdala, and 
prefrontal cortex to the nucleus accumbens (Mogenson and Yang, 1991; Yoshi-
kava et al., 1991). However, according to our results and those by Bozarth et al. 
(1994) we speculate that glutamate likewise participates in such components of 
morphine reinforcement that are motivational in nature and relatively inde­
pendent on associative learning or mesotelencephalic dopamine. A characteris­
tic feature of the glutamatergic circuits in the central nervous system gives sup­
port to this proposal, for as stated by Kaliwas (1995) "... considering the wide­
spread distribution of EAA (exitatory amino acids)-ergic projections, it is likely 
that any relatively global modification of neurotransmission in the brain, such 
as that produced by systemic administration of a drug of abuse, will ultimately 
impact on EAA transmission". 
There are, however, at least two alternative explanations for L-NOARG's 
effect, which cannot be excluded on the basis of the present study. First, 
L-NOARG may have altered the pharmacokinetics of morphine due to its vas­
cular effects. Though behavioral results suggest that the pharmacokinetic area-
under-the-curve of cocaine was unaffected by the inhibition of NO synthase 
(Bozarth et al., 1994), it does not imply morphine. Second, L-NOARG may 
have interfered with the effect of morphine due to the inhibition of locomotor 
activity (Starr and Starr, 1995). However, at least the acute effect of the drug on 
motor behavior may be ruled out as the postconditioning test was carried out 24 
hours after the last L-NOARG administration. Moreover, the decreased loco­
motor activity has been shown to enhance the expression of morphine-induced 
place preference (Neisewander et al., 1990). 
7. CONCLUSIONS 
1) The activation of pi opioid receptors is critical in the positive reinforcing 
properties of morphine, whereas the 5 opioid receptors could be insignificant in 
this respect. The results also confirm the importance of |il opioid receptors in 
the mediation of morphine-induced antinociception and catatonia. 
2) As far as the place preference paradigm is concerned, the activation of do­
pamine autoreceptors appears insufficient to reliably modify the positive rein­
forcing effects of both morphine and cocaine. Furthermore, there is a diver­
gence in the endogenous pathways that mediate positive reinforcing properties 
of |Li-opioids (morphine) and psychomotor stimulants (cocaine). Reinforcing 
effects of morphine involve some dopamine-independent mechanisms, whereas 
concerning cocaine the role of brain dopamine is critical. 
3) Both acute morphine administration and withdrawal from repeated morphine 
treatment may induce the supersensitivity of dopamine D2/D3 receptors. How­
ever, in the case of acute morphine administration the expression of this super­
sensitivity in behavioral level is inhibited by concomitant activation of dopa­
mine D1 receptors. The significance of the supersensitive D2/D3 receptors with 
respect to morphine as a positive reinforcer remains, however, an unresolved 
question. 
4) NO is involved in the positive reinforcing properties of morphine. This in­
volvement is apparently related to the motivational rather than mnemonic com­
ponents of the reinforcement process. Besides, there is no commitment of NO 
in the aversive properties of K opioids. 
5) There are reward pathways in the brain, the activity of which is not sup­
pressed by the inhibition of the mesotelecephalic dopaminergic system. The 
activation of these reward pathways by ji-opioids appears sufficient to produce 
positive reinforcing effects. These mechanisms are related to endogenous 
opioid systems and involve jul receptors. We propose also the participation of 
glutamate / NO cascade. 
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RAVIMISÕLTUVUSE MEHHANISMID: 
TÄHELEPANU KESKMES ON MORFIINI 
POSITIIVSED SARRUSOMADUSED 
Kokkuvõte 
Töö eesmärgiks oli selgitada: 
— ja-opioidiretseptorite alatüüpide ning Ö-opioidiretseptorite osa morfiini posi­
tiivsetes sarrusomadustes (positive reinforcing properties). Käitumismude-
lina kasutasime tingitud paigaeelistust rottidel. Uurisime selektiivse 
(il-opioidiretseptori antagonisti naloksonasiini ning 5-retseptori antagonisti 
naltrindooli mõju morfiiniga indutseeritud paigaeelistusele. Võrdlusena 
uurisime ka mitteselektiivse opioidiretseptorite antagonisti naltreksooni 
toimet. Naloksonasiini selektiivsuse hindamiseks uurisime selle mõju mor­
fiini analgeetilisele, hüpertermilisele ning katatoonilisele toimele. 
— Kesknärvisüsteemi dopamiinergilise süsteemi osa morfiini positiivsetes 
sarrusomadustes rõhuasetusega dopamiini autoretseptoritel. Dopamiinergi­
lise substraadi kriitilisuse korral võiksid dopamiini autoretseptoreid akti­
veerivad (ja seetõttu dopamiinergilist neurotransmissiooni pärssivad) ained 
pärssida ka morfiini positiivseid sarrusefekte. Selle hüpoteesi kontrolli­
miseks uurisime rottidel dopamiini D2/D3-retseptorite agonisti kvinpirooli 
ning dopamiini autoretseptorite agonisti preklamooli mõju morfiiniga indut­
seeritud paigaeelistusele. Võrdluseks uurisime ka nimetatud ainete mõju 
kokaiiniga indutseeritud paigaeelistusele. 
— Dopamiini D2/D3-retseptorite tundlikkuse muutusi morfiini akuutse ning 
kroonilise manustamise korral. Selleks uurisime rottidel morfiini akuutse 
ning kroonilise manustamise mõju kvinpirooliga indutseeritud käitumistele 
(haigutamiskäitumine, lokomotoorse aktiivsuse muutused, stereotüüpia). 
— Lämmastikoksiidi (NO) osa morfiini positiivsetes sarrusomadustes. Uuri­
sime NO süntetaasi inhibiitori L-NOARG-i mõju morfiiniga indutseeritud 
paigaeelistusele. Mälu ning motivatsiooniga seotud protsesside osatähtsuse 
hindamiseks uurisime ka L-NOARG-i mõju K-opioidiretseptori agonisti 
U50,488-ga indutseeritud paigavältimisele. 
Morfiin (3 mg/kg SC) indutseeris statistiliselt olulise paigaeelistuse, mis on 
hästi kooskõlas varasemate töödega (van der Kooy, 1987). Seda toimet pärssi-
sid oluliselt mitteselektiivne opioidiretseptorite antagonist naltreksoon 
(2,5 mg/kg SC) ja selektiivne (ul-opioidiretseptori antagonist naloksonasiin 
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(15 mg/kg IP). Naloksonasiin pärssis ka morfiini analgeetilist ning katatoonilist 
toimet, kuid ei mõjustanud oluliselt morfiini hüpertermilist efekti. Nende 
tulemuste põhjal väidame, et antud annuse ning manustamisviisi korral 
(s.t. 15 mg/kg DP) toimis naloksonasiin valikuliselt JLII opioidretseptori suhtes. 
Selektiivne 8-opioidiretseptori antagonist naltrindool (2 mg/kg EP) morfiiniga 
indutseeritud paigaeelistusele olulist mõju ei avaldanud. 
Kvinpiroolil (0,05 mg/kg SC) ning preklamoolil (8 mg/kg SC) ei olnud 
olulist mõju morfiini paigaeelistusele. Preklamool, manustatuna suhteliselt suu­
res doosis (8 mg/kg) pärssis kokaiiniga (5 mg/kg IP) indutseeritud paiga-
eelistust, kuid seda oletatavasti osaliselt või täielikult postsünaptiliste dopa-
miiniretseptorite blokeerimise tõttu. 
Morfiini akuutne (3 mg/kg SC) ning krooniline (20-50 mg/kg/24 h 7 päeva 
jooksul) manustamine põhjustasid dopamiini D2/D3-retseptorite tundlikkuse 
suurenemise kvinpirooli suhtes. Sellise nähtuse peamiseks avalduseks oli kvin-
pirooliga (0,01-0,1 mg/kg SC) indutseeritud haigutamiskäitumise suurem inten­
siivsus morfiini grupi loomadel. Morfiini akuutse manustamise korral tekkis 
selline toime 90 min pärast morfiini injektsiooni ning selle avaldumiseks oli 
vajalik dopamiini Dl-retseptorite blokaad. 
NO sünteesi inhibeerimine L-NOARG-ga (20 mg/kg EP) pärssis rottidel olu­
liselt morfiiniga indutseeritud paigaeelistust. L-NOARG ise olulist paigatingi-
muslikku toimet ei põhjustanud. Kuna L-NOARG ei mõjutanud oluliselt ka 
K-opioidiretseptori agonisti U-50,488-ga indutseeritud paigavältimist, siis oleta­
me, et NO sünteesi inhibeerimine põhjustas muutusi morfiini motivatsiooniga 
seotud sarruskomponentides. 
Järeldused 
1. ^il-opioidiretseptori aktivatsioonil on keskne roll morfiini positiivsetes 
sarrusomadustes. Seevastu 8-opioidiretseptori aktivatsioon olulist tähendust 
morfiini korral ilmselt ei oma. Samuti kinnitavad käesoleva töö tulemused 
(j.l-opioidiretseptori olulist osa morfiini analgeetilises ning katatoonilises 
toimes. 
2. Dopamiini autoretseptorite aktivatsioon ei ole küllaldane faktor, et mõju­
tada oluliselt nii morfiini kui ka kokaiini positiivseid sarrusomadusi. |i-opioi-
dide (morfiini) ning psühhomotoorsete stimulaatorite (kokaiini) positiivseid 
sarrusomadusi vahendavates endogeensetes närviteedes on olulised erinevused. 
Morfiini sarrusomadused sisaldavad dopamiinist sõltumatuid komponente, 
seevastu kokaiini korral on dopamiinergilistel mehhanismidel keskne roll. 
3. Nii akuutne kui ka krooniline morfiini manustamine võib põhjustada do­
pamiini D2/D3-retseptorite suurenenud tundlikkust. Akuutse morfiini manusta­
mise korral on sellise toime avaldumine käitumuslikul tasemel aga varjutatud 
samaaegse D1 -retseptorite aktivatsiooni poolt. Mis aga puutub morfiini posi­
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tiivsetesse sarrusomadustesse, siis dopamiini D2/D3-retseptorite suurenenud 
tundlikkuse olulisus jääb stilles suhtes ebaselgeks. 
4. NO osaleb morfiini positiivseid sarrusomadusi vahendavates närviteedes. 
See roll on seotud pigem sarrusefekti motivatsioonilise kui mäluga seotud 
komponendiga. K-opioidide aversiivsetes toimetes NO ilmselt ei osale. 
5. Ajus eksisteerivad positiivse sarrustuse mehhanismid, mille aktiivsus 
säilib ka pärast mesotelentsefaalse dopamiinergilise süsteemi pärssimist. Need 
mehhanismid on seotud endogeensete opioidsüsteemidega ning oluline roll on 
neis |LL1-opioidiretseptorite!. Me oletame, et nendes närviteedes osalevad ka NO 
ja glutamaat. 
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KIVASTIK, T„ K. VUORIKALLAS, T. P. PIEPPONEN, A. ZHARKOVSKY AND L. AHTEE. Morphine- and co-
caine-induced conditioned place preference: Effects of quinpirole and preclamol. PHARMACOL BIOCHEM BEHAV 
5-1(2) 371-375, 1996. —The role of dopamine in opioid reward is unresolved. Furthermore, ihe issue is somewhat unclear 
regarding cocaine and the place preference paradigm. In Ihe present study we investigated whether the drugs activating 
dopamine autoreceptors affect cocaine- and morphine-induced place preference in rats. Neither the dopamine D2/D3  receptor 
agonist, quinpirole (0.05 mg/kg, SC), nor the partial dopamine autoreceptor agonist, preclamol (2 or 8 mg/kg, SC), induced 
place conditioning by itself. Quinpirole had no significant influence on the place preference induced either by morphine (3 
mg/kg, SC) or cocaine (5 mg/kg, IP). Preclamol, when given at the dose of 8 mg/kg SC, significantly attenualed the effect of 
cocaine but failed lo modify Ihe effeel of morphine. Our results suggest thai the rewarding properties of morphine involve 
DA-independeni mechanisms whereas in the cocaine-induced reward Ihe role of brain DA is critical. Furthermore, as regards 
place conditioning, we propose that the aciivaiion of DA autoreceptors is no! sufficient lo reliably modify the rewarding 
effect of cocaine. 
Rew ard Cocaine Morphine DA aulorecepiors Quinpirole Preclamol Rais Place preference 
MOTIVATIONAL effects of addictive drugs have been attrib­
uted to the interaction of exogenous substances with endoge­
nous reward pathways. A great deal of evidence suggests that 
the mesolimbic dopamine (DA) system could serve as a com­
mon neural substrate mediating the appetitive properties of 
different classes of drugs. Thus, a common feature for many 
addictive drugs, including opioids and psychomotor stimu­
lants, is their ability to enhance the mesolimbic DA transmis­
sion (11). 
Behaviourally relevant doses of opioids enhance both the 
firing of the dopaminergic neurons in the ventral tegmental 
area (22) and the release of DA in the nucleus accumbens (11). 
Several studies have demonstrated that DA receptor antago­
nists and lesions of dopaminergic neurons interfere with Ihe 
opioid reward (2,30,32). One can find data, however, to indi­
cate that the reinforcing actions of opioids may also involve 
DA-indcpendent mechanisms. Thus, DA antagonists do not 
reduce the self-administration of heroin unless given in doses 
causing motor impairment (12). Furthermore, il has been 
demonstrated that selective lesions of the DA terminals in the 
nucleus accumbens significantly attenuate the self-administra-
tion of cocaine but not that of heroin (25). 
The rewarding properties of cocaine appear to depend on 
the integrity of the mesolimbic DA system as measured by IV 
drug self-administration (26). However, the issue is somewhat 
unclear regarding the place conditioning paradigm because 
both the neuroleptic drugs and the 6-hydroxydopamine (6-
OHDA) lesions of the nucleus accumbens have failed to in­
fluence conditioned place preference (CPP) induced by IP 
cocaine (23,33). Still, the effect of either ICV- or IV-administ-
ered cocaine was blocked by pimozide (23) and haloperidol 
(34), respectively. In view of these data, it has been questioned 
| Present address: University of Tarlu, Department of Pharmacology, EE2400 Tartu, Estonia. 
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whether the effect of IP cocaine truly reflects its central re­
warding properties, and alternative explanations have been 
proposed, including local anaesthetic action of cocaine (33). 
Drug discrimination studies (9), though, do not support the 
local anaesthesia hypothesis. Furthermore, according to a re­
cent place conditioning study (17), clozapine impairs the effect 
of IP-administered cocaine, and another study (14) clearly 
demonstrates the predominant involvement of central compo­
nents in the CPP induced by IP cocaine. 
The activity of the mesolimbic DA system is regulated by a 
negative feedback mechanism that involves DA receptors lo­
cated on the DA cell itself (i.e., autoreceptors). Thus, DA and 
exogenous DA agonists inhibit the firing of most midbrain 
dopaminergic neurons by stimulating DA autoreceptors (6). 
DA autoreceptors exhibit pharmacological characteristics of 
DA D,-like receptors (35). It has been demonstrated that D3 
receptors, known to be D2-like, also act as autoreceptors (31). 
According to some recent studies, DA autoreceptors could 
be implicated in the rewarding and discriminative stimulus 
properties of cocaine (4,5). 
Biochemical and behavioural investigations indicate that the 
selective DA D2/DJ receptor agonist quinpirole (LY171555) in 
small doses could act selectively at DA autoreceptors (36,38). 
Preclamol ([-)3PPP) is a partial DA autoreceptor agonist 
that also exhibits antagonistic properties at postsynaptic DA 
receptors [for extensive review see (7,8)]. 
The present study was devised to further clarify the role of 
brain DA in cocaine and morphine reward , with an emphasis 
on DA autoreceptors. Our idea was that drugs activating DA 
autoreceptors, and hence decreasing DAergic transmission, 
could interfere with morphine and cocaine reward. To test this 
hypothesis, a series of experiments was carried out, where we 
investigated whether quinpirole or preclamol affect cocaine-
and morphine-induced place preference. 
METHOD 
Animals 
Male Wistar rats weighing 250-400 g were used. The rats 
were housed in groups of four to five with food and water 
available ad lib, under 12 L : 12 D cycle (lights on at 0600 h). 
The experiments were carried out during the light phase of the 
cycle. 
Drugs 
The doses of drugs, except morphine, refer to the salt. The 
dose of morphine refers to the amount of the free base. All 
compounds were dissolved in 0.9% NaCl solution and injected 
in a volume 2 ml/kg. Morphine HCl (Ph. Eur. 2nd ed.) was 
administered SC into the neck region. Cocaine HCl (Ph. Eur. 
2nd ed.) was injected IP. Quinpirole HCl (LY 171555; gift 
of Eli Lilly & Co, Indianapolis, IN) and preclamol HCl 
([ -]3PPP; RBI, Natick, MO, and gift of Suomen Astra OY) 
were administered SC into the neck region. The doses of pre­
clamol (2 or 8 mg/kg, SC) used were based on biochemical 
and behavioural studies where they were found to inhibit DA 
synthesis in autoreceptor models (7) and cocaine discrimina­
tion [(5); for further information about doses and pretreat-
ment intervals see the Experimental Procedure section]. 
Place Preference Apparatus 
An apparatus similar to that described previously (18) was 
used. It consisted of two square-base compartments (h 40 x 
30 x 30 cm), one with white and the other with gray walls 
and floor. Compartments were separated by a guillotine door 
and were covered with a transparent Plexiglas ceiling. The 
apparatus was placed into a dimly lit room with masking noise 
provided by ventilation fan. 
Experimental Procedure 
Before starting the experiment the rats were acclimated to 
experimenter contact for 3 days by handling and weighing in 
the experiment room. 
Each experiment consisted of three phases. 
1. Preconditioning; For 3 days (days I, 2, and 3) rats were 
given free access to both compartments of the apparatus 
for 15 min (900 s) each day. On day 3, the time spent by 
rats in each compartment was recorded and these values 
served as a baseline. 
2. Conditioning was conducted for 4 days (days 4, 5, 6, and 7) 
and included two sessions each day. The rats were condi­
tioned in the initially nonpreferred chamber after adminis­
tration of morphine (3 mg/kg, SC) or cocaine (5 mg/kg, 
IP), and in the preferred one after administration of saline. 
An interval of 4 h separated the two sessions. The order of 
drug (i.e., morphine or cocaine) and saline presentation, 
paired with the given environment, was balanced across 
treatment groups. Conditioning times of 60 and 45 min 
were used for morphine and cocaine, respectively. Quinpir­
ole (0.05 mg/kg, SC) was administered 5 and 10 min be­
fore morphine and cocaine, respectively. Preclamol (2 or 8 
mg/kg) was given 15 min before morphine or cocaine ad­
ministration. For assessing the conditioning induced by 
quinpirole and preclamol, separate groups of rats were 
administered saline immediately, and quinpirole 5 min or 
preclamol 15 min before placing the rat in the nonpreferred 
chamber. 
3. Postconditioning: On day 8 no injections were given. The 
rats had free choice in the apparatus for 15 min and the 
time spent in each chamber was recorded. 
Statistics 
The data from each drug combination were subjected to 
two-factor analysis of covariance (ANCOVA) where the time 
spent in the drug-paired compartment during postcondition­
ing test served as dependent variable, pretreatment (quinpirole 
or preclamol) and treatment (morphine or cocaine) as categor­
ical variables, and the baseline as covariate. Where necessary, 
post hoc comparisons were conducted by using the contrast 
analysis with Bonferroni levels (i.e., the critical level 0.05 was 
divided by the number of the comparisons made). 
RESULTS 
Figure 1A shows that neither quinpirole (0.05 mg/kg) nor 
preclamol (2 or 8 mg/kg) induced a significant place condi­
tioning effect. 
Cocaine induced significant CPP, F{ 1, 69) = 18.9, p < 
0.01. This effect was significantly impaired by 8 mg/kg of 
preclamol but was unaffected by quinpirole and preclamol at 
the dose 2 mg/kg (Fig. IB). In fact, the ANCOVA revealed a 
nonsignificant quinpirole x cocaine interaction, F(l, 69) = 
0.44, p = 0.5, whereas the preclamol X cocaine interaction 
was significant, F(2, 70) = 5.1 ,p = 0.009. Post hoc compar­
isons showed that there was no significant, difference between 
the treatment groups preclamol 2 mg/kg + cocaine and saline 
+ cocaine, whereas the difference between the groups precla-
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FIG. 1. Effect of quinpirole and preclamol on conditioned place 
preference (CPP) induced by morphine or cocaine in rats. (A) The 
effect of quinpirole and preclamol in saline-treated control rats. (B) 
The effect of drugs on CPP induced by cocaine (5 mg/kg, IP). (C) 
The effect of drugs on CPP induced by morphine (3 mg/kg, SC). The 
columns depict the mean ± SE lime spent in the initially nonpre­
ferred (i.e., drug-paired) compartment during preconditioning (open 
columns) and postconditioning (filled columns) tests. Abbreviations 
under columns indicate the pretrealment during conditioning: sal — 
saline, Q-quinpirole (0.05 mg/kg, SC), P2-preclamol (2 mg/kg, 
SC), P8-preclamol (8 mg/kg, SC). Number of animals in parenthe­
ses. Hp < 0.01 compared with control (saline + saline) group; *p < 
0.05 compared with saline-pretreated cocaine group (contrast analysis 
with Bonferroni adjustment). 
mol 8 mg/kg + cocaine and saline + cocaine was significant, 
Fd, 70) = 6.45, p = 0.013. 
Morphine also induced significant CPP, F(l, 67) = 14.56, 
p < 0.01, but neither quinpirole nor preclamol (8 mg/kg) had 
significant influence on this effect (Fig. 1C). 
In our study conditioned place preference induced by co­
caine was significantly attenuated by the partial DA autore­
ceptor agonist, preclamol (8 mg/kg), but not by the DA D2/D3 
receptor agonist, quinpirole. Neither preclamol nor quinpirole 
significantly influenced the CPP induced by morphine. Quin­
pirole and preclamol by themselves had no place conditioning 
clfccl. The finding that quinpirole lacked the effect on place 
conditioning at a dose of 0.05 mg/kg agrees with the earlier 
results, indicating that quinpirole can induce CPP within the 
limited dose range (0.1-1.0 mg/kg), whereas smaller and 
larger doses are ineffective (15,37). 
Our data agree with the recent results demonstrating that 
preclamol dose-dependently (0.625-10 mg/kg) reduces the dis­
criminative stimulus properties of cocaine (5). However, it 
appears that the activation of DA autoreceptors is not suffi­
cient to antagonize cocaine reward, because quinpirole and 
the smaller dose of preclamol that was shown to activate the 
autoreceptors (1) were ineffective. Quinpirole, acting upon 
DA autoreceptors, reduces the release of DA both in vivo (28) 
and in vitro (3), yet it does not block it entirely. It has been 
shown, furthermore, that only extensive lesions (>90%) with 
6-OHDA could effectively reduce psychomotor stimulant re­
ward (26,27). Martin-Iverson et al. (21), proceeding from their 
work with indirect DA agonists, methylphenidate and nomi­
fensine, proposed that "... even a slight increase in activa­
tion of DA receptors could be sufficient to produce a reward­
ing effect." Such an explanation also seems to be appropriate 
in our case, to interpret the lack of quinpirole's effect. It is 
also unclear to what extent quinpirole at such a small dose 
(0.05 mg/kg) activates the postsynaptic DA receptors. How­
ever, the discriminative stimulus properties of 0.05 mg/kg SC 
of quinpirole were shown to be mediated via DA autorecep­
tors (38). Preclamol, besides being a partial DA autoreceptor 
agonist, has antagonistic properties on postsynaptic DA recep­
tors (7,8). Therefore, the effect of the larger dose of preclamol 
could be due to either its postsynaptic action or to the combi­
nation of its pre- and postsynaptic actions. 
A recent self-administration study (4) demonstrated that 
the Dj receptor agonists quinpirole and 7-hydroxy-N,Ar-di-n-
propyl-2-aminotetraline (7-OH-DPAT), when coadministered 
with cocaine (at doses that were not self-administered by 
themselves), reduced cocaine intake by increasing the intervals 
between injections without disrupting self-administration. The 
same effect occurs when the dose of cocaine is increased (39). 
Because 7-OH-DPAT did not alter self-administration of a 
direct DA agonist, apomorphine, the authors suggested that 
" . . . D, selective dopamine agonists may interact presynapti-
cally to enhance cocaine's reinforcing properties." The results 
of our study, however, do not agree with this proposal, for 
quinpirole neither potentiated nor inhibited the effect of co­
caine. One of the reasons for this discrepancy could be the 
difference in paradigms used: IV self-administration vs. CPP. 
As far as IV self-administration is concerned, the animals are 
tested under direct influence of drugs (that is not the case in 
CPP). Thus, besides the changes in reinforcing effects, the 
changes in motor behaviour may be underlying: a decrease or 
increase in response rate may result from an inhibition or 
17 
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stimulation of motor behaviour, respectively (39). Because 
both 7-OH-DPAT and quinpirole in "autoreceptor-selective" 
doses reduce locomotor activity (10,16), their direct influence 
on test performance may serve as a confounding factor. How­
ever, the fact that 7-OH-DPAT did not alter self-administra­
tion of apomorphine (4) could possibly rule it out. An alterna­
tive explanation for the inconsistency in ours vs. Caine and 
koob's results is thai CPP and IV sell-administration, due 
ID some fundamental differences, reflect different aspects of 
cocaine reward (e.g., in the case of the former paradigm the 
acquisition phase is routinely studied whereas the latter one 
considers usually the maintenance). This view is further sus­
tained by the discrepancy in results concerning clozapine's ef­
fect on cocaine self-administration and CPP (17,19). 
A substantial body of evidence refers to the central role of 
the dopaminergic substrate in opioid reward (2,30,32). More­
over, a recent place conditioning study (29) suggests the signif­
icance of DA D, receptor in the nucleus, accumbens [but see 
below and (13)]. It was also demonstrated that selective DA 
D, receptor antagonist, SCH23390, over a large dose range 
increases the responding for heroin, which was interpreted as 
a decrease in heroin reward (24). On the other hand, several 
studies do not agree with such a DA hypothesis (12,20,25). 
Thus, DA receptor antagonist, a-flupentixol, although elimi­
nating IV self-administration of cocaine, did not reduce self-
administration of heroin, unless given in doses impairing loco­
motor activity (12). Neither did small doses of u-flupentixol 
cause a compensatory increase in responding for heroin (12). 
Likewise, SCH23390 affects the initiation of heroin self-
administration only in doses that inhibit motor behaviour as 
well (13). In our study preclamol, at the dose that impaired the 
effect of cocaine, did not affect significantly place preference 
induced by morphine. Hence, our data agree with the earlier 
reports indicating the existence of different endogenous sub­
strates in opioid and psychomotor stimulant reward. 
In conclusion, the results of the present study confirm Ihe 
involvement of the central DAergic substrate in CPP induced 
by IP cocaine. Furthermore, our data suggest that the endoge­
nous pathways mediating rewarding effects of morphine and 
cocaine differ. Rewarding properties of morphine appear to 
also involve DA-independent mechanisms, whereas in the case 
of cocaine the role of brain DA is critical. However, the role 
of DA autoreceptors remains fairly unclear. Thus, cocaine-
induced CPP was impaired by preclamol at a dose that may 
have antagonistic properties at postsynaptic DA receptors, 
whereas a small dose of preclamol as well as quinpirole in an 
"autoreceptor-selective" dose lacked the effect. We propose 
that, as far as the place preference paradigm is concerned, the 
activation of DA autoreceptors is not sufficient to reliably 
modify the rewarding effect of cocaine. 
ACKNOWLEDGEMENTS 
This work was supported by University of Helsinki, The Sigrid 
Juselius Foundation, The Finnish Cultural Foundation, and CI MO 
(Center for International Mobility, Helsinki). Preclamol was kindly 
supplied by Stiomcn Astra OY. 
REFERENCES 
1. Arm, J. Differential behavioural effects of dopamine agonists in 
developing rats: A study of 3-PPP enaniiomers. Eur. J. Pharma­
col. 91:273-278; 1983. 
2. Bozarth, M. A.; Wise, R. A. Heroin reward is dependent on a 
dopaminergic substrate. Life Sei. 29:1881-1886; 1981. 
3. Bull, D. R.; Sheenan, M. J. Presynaptic regulation of electrically 
evoked dopamine overflow in nucleus accumbens: A pharma­
cological study using fast cyclic voltammetry in vitro. Naunyn 
Schmiedebergs Arch. Pharmacol. 343:260-265; 1991. 
4. Caine, S. B.; Koob, G. F. Modulation of cocaine self-
administration in the rat through D, dopamine receptors. Science 
260:1814-1816; 1993. 
5. Callahan, P. M.; Cunningham, K. A. Discriminative properties 
of cocaine in relation to dopamine D ;  receptor function in rats. J. 
Pharmacol. Exp. Ther. 266:586-592; 1993. 
6. Carlsson, A. Receptor mediated control of dopamine metabo­
lism. In: Usdin, E.; Bunney, W. E., edii. Pre- and postsynaptic 
receptors. New York: Marcel Dekker; 1975:49-65. 
"I. Clark, D., Hjorih, S.; Carlsson, A. Dopamine-receplor agonists: 
Mechanisms underlying auloreceptor selectivity. 1. Review of evi­
dence. J. Neural Transm. 62:1-52; 1985. 
8. Clark, D.: Hjorth, S.; Carlsson, A. Dopamine-receptor agonists: 
Mechanisms underlying autoreceptor selectivity, li. Theoretical 
considerations. J. Neural Transm. 62:171-207; 1985. 
9. Colpaert, F. C.; Niemegeers, J. E.; Janssen, P. A. J. Discrimina­
tive stimulus of cocaine: Neuropharmacologicai characteristics as 
derived from from stimulus generalization experiment. Pharma­
col. Biochem. Behav. 10:535-546; 1979. 
10. Daly, S. A.; Waddington, J. L. Behavioural effects of the puta­
tive Dj dopamine receptor agonist 7-OH-DPAT in relation lo 
other "Dj-like" agonists. Neuropharmacology 32:509-510; 1993. 
11. Di Chiara, G.; Imperato, A. Drugs abused by humans preferen­
tially increase synaptic dopamine concentrations in the mesolim­
bic system of freely moving rats. Proc. Natl. Acad. Sei. USA 85: 
5274-5278; 1988. 
12. Ettenberg, A.; Peuit, H. O.; Bloom, F. E.; Koob, G. F. Heroin 
and cocaine intravenous self-administration in rats: Mediation by 
separate neural systems. Psychopharmacology (Berlin) 78:204-
209; 1982. 
13. Gerrits, M. A. F. M.; Ramsey, N. F.; Wollerink, G.; van Ree, J. 
M. Lack of evidence for an involvement of nucleus accumbens 
dopamine D, receptors in the initiation of heroin self-administra­
tion in the rat. Psychopharmacology (Berlin) 114:486-494; 1994. 
14. Hemby, S. li.; Jones, G. H.; Huberl, G. W.; Ncill, D. B.; Justice, 
Jr. Assessment of the relative contribution of peripheral and cen­
tral components in cocaine place conditioning. Pharmacol. Bio­
chem. Behav.47:973-979; 1994. 
15. Hoffman, D. C.; Dickson, P. R.; Beninger, R. J. The dopamine 
D. receptor agonists, quinpirole and bromocriptine produce con­
ditioned place preferences. Prog. Neuropsychopharmacol. Biol. 
Psychiatry 12:315-322; 1988. 
16. Jackson, D. M.; Ross, S. B.; Larsson, L.-G. Dopamine D, recep-
lor agonist-induced behavioural depression: Critical dependence 
upon postsynaptic dopamine D, function. A behavioural and bio­
chemical sludy. Naunyn Schmietlebcrgs Arch. Pharmacol. 340: 
355-365; 1989. 
17. Kosten, T. A.; Nestler, E. J. Clozapine attenuates cocaine condi­
tioned place preference. Life Sei. 55:PL9-I4; 1994. 
18. Leone, P.; Di Chiara; G. Blockade of D, receptors by SCH23390 
antagonizes morphine- and amphetamine-induced place prefer­
ence conditioning. Eur. J. Pharmacol. 135:251 -254; 1987. 
19. Loh, E. A.; Fitsch, T. S.; Vickers, G.; Roberts, D. C. S. Clozap­
ine increases breaking points on a progressive-ratio schedule rein­
forced by intravenous cocaine. Pharmacol. Biochem. Behav. 42: 
559-562; 1992. 
20. Mackey, W. B.; van der Kooy, D. Neuroleptics block the positive 
reinforcing effect of amphetamine but not of morphine as mea­
sured by place preference conditioning. Pharmacol. Biochem. Be­
hav. 22:101-105; 1985. 
21. Martin-lverson, M. T.; Ortmann, R.; Fibiger, H. C. Place condi­
tioning with methylphenidate and nomifensine. Brain Res. 332: 
59-67;1985. 
DA AUTORECEPTORS AND REWARD 375 
22. Matthews, R. T.; German, D. C. Electrophysiological evidence 
for excitation of rat ventral tegmental area dopamine neurons by 
morphine. Neuroscience 11:617-625; 1984. 
23. Morency, M. A.; Beninger, R. J. Dopaminergic substrates of 
cocaine-induced place conditioning. Brain Res. 399:33-41; 1986. 
24. Nakajima, S.; Wise, R. A. Heroin self-administration in the rat 
suppressed by SCH23390. Soc. Neurosci. Abstr. 13:1545; 1987. 
25. Pettit, H. O.; Ettenberg, A.; Bloom, F. E.; Koob, G. F. Destruc­
tion of dopamine in nucleus accumbens selectively attenuates co­
caine but not heroin self-administration. Psychopharmacology 
(Berlin) 84:167-173; 1984. 
26. Roberts, D. C. S; Corcoran, M. E.; Fibiger, H. C. On the role of 
ascending catecholaminergic systems in intravenous self-
administration of cocaine. Pharmacol. Biochem. Behav. 6:615-
620; 1977. 
27. Roberts, D. C. S.; Koob. G. F.; Klonoff, P.; Fibiger. H. C. 
Extinction and recovery oi cocaine self-administration following 
6-hydroxydopamine lesions of the nucleus accumbens. Pharma­
col. Biochem. Behav. 12:781-787; 1979. 
28. See, R. E.; Sorg. B. A.; Chapman, M. A.; Kalivas, P. W. In 
vivo assessment of release and metabolism of dopamine in the 
ventrolateral striatum of wake rats following administration of 
dopamine D, and D ;  receptor agonists and antagonist. Neuro­
pharmacology 30:1269-1274; 1991. 
29. Shippenberg, T S.; Bals-Kubik, R.; Herz, A. Examination of the 
neurochemical substrates mediating the motivational effects of 
opioids: Role of the mesolimbic dopamine system and D, vs. D ;  
dopamine receptors. J. Pharmacol. Exp. Ther. 265:53-59; 1993. 
30. Smith, J. E.; Guerin, G. F.; Conchita, C. O.; Barr, T. S.; Lane, 
J. D. Effects of 6-OHDA lesions of the central medial nucleus 
accumbens on rat intravenous morphine self-administration. 
Pharmacol. Biochem. Behav. 23:843-849; 1985. 
31. Sokoloff, P.; Giros, B.; Marets, M.-P.; Bouthcnet, M.-L.; 
Schwartz, J.-Ch. Molecular cloning and characterization of a 
novel dopamine receptor (Dj) as a target for neuroleptics. Nature 
347:146-151; 1990. 
32. Spyraki, C.; Fibiger, H. C.; Phillips, A. G. Attenuation of heroin 
reward by disruption of the mesolimbic dopamine system Psycho­
pharmacology (Berlin) 79:278-283; 1982a. 
33. Spyraki, C.; Fibiger, H. C.; Phillips, A. G. Cocaine-induced 
place preference conditioning: lack of effects of neuroleptics and 
6-hydroxydopamine lesions. Brain Res. 253:195-203; 1982. 
34. Spyraki, C.; Nomikos, G. G.; Varonos, D. D. Intravenous co-
eaine-induced place preference: Attenuation by haloperidol. Be­
hav. Brain Res. 26:57-62; 1987. 
35. White, F. J.; Wang, R. Y. Pharmacological characterization of 
dopamine autoreceptors in rat ventral tegmental area: Microion-
tophorelic studies. J. Pharmacol. Uxp. Ther. 231:275-280; 1984. 
36. White, F. J.; Wang, R. Y. Electrophysiological evidence for the 
existence of both D, and D, dopamine receptors in Ihe rat nucleus 
accumbens. .1. Neurosci. 6:274-280; 1986. 
37. White, N. M.; Packard, M.G.; Hiroi, N. Place conditioning with 
dopamine D, and Dj agonists injected peripherally or into nucleus 
accumbens. Psychopharmacology (Berlin) 103:271-276; 1991 
38. Widzowski, D. V.; Gori-Slechta, D. A. Apparent mediation of 
stimulus properties of a low dose of quinpirole by dopaminergic 
autoreceptors. J. Pharmacol. Exp. Ther. 266:526-534; 1993. 
39. Yokel, R. A. Intravenous self-administration: Response rates, the 
effects of pharmacological challenges, and drug preference. In: 
Bozarth, M. A., ed. Methods of assessing the reinforcing proper­
ties of abused drugs. Berlin: Springer; 1987:1-33. 
II  
18 
Kivastik, T.( Rutkauskaite, J., Zharkovsky, A. 
Nitric oxide synthesis inhibition attenuates 
morphine-induced place preference. 
Pharmacology Biochemistry and Behavior, 53: 1013-1015, 1996. 
Sl 
I I Sl VII K 
Nitric Oxide Synthesis Inhibition Attenuates 
Morphine-Induced Place Preference 
T. KIVASTIK, J. RUTKAUSKAITE AND A. ZHARKOVSKY1 
Department of Pharmacology, University of Tartu, Ülikooli 18, EE2400 Tartu, Estonia 
Received 22 May 1995 
KIVASTIK. T., J. RUTKAUSKAITE AND A. ZHARKOVSKY. Nitric oxide synthesis inhibition attenuates morphine-
induced place preference. PHARMACOL BIOCHEM UEHAV 53(4) 1013-1015, 1996. - Nilric oxide (NO) has been impli­
cated in ihe actions of opioids. The aim of the present study was to investigate the role of NO in the mechanisms mediating 
the rewarding effects of morphine. Therefore, the influence of NO synthase inhibitor L-Mnitroarginine (L-NOARG) on 
morphine-induced place preference in rats was studied. t.-NOARG, when given at 20 mg/kg, IP, significantly inhibited the 
effect of morphine. I -NOARG by itself, when administered at 5 or 20 mg/kg, IP, appeared to have no reliable effect on place 
conditioning. The results suggest a possible role of NO in the opioid reward process. 
Nitric oxide Morphine Place preference Rats 
Pharmacology Biochemistry and Behavior, Vol. 53, No. 4, pp. 1013-1015, 1996 
Copyrightc 1996 Elsevier Science Inc. 
Printed in the USA. All rights reserved 
0091-3057/96 $15.(X) + .(HI 
SSIM 0091-3057(95)02092-6 
THE FREE RADICAL gas nitric oxide (NO) is a highly un­
conventional messenger molecule. Its function in the CNS is 
widely related to excitatory amino acids. Thus, NO is formed 
in response to glutamate acting upon NMDA receptor, and 
its release is involved in many glutamate actions in the CNS 
including cellular events that may underlie the processes of 
learning and memory (12). According to the results of recent 
studies, NO may be implicated in the actions of opioids; it 
has been demonstrated that inhibitors of NO synthase could 
prevent morphine tolerance (6) and attenuate the development 
and expression of the abstinence syndrome (5). The issue is 
largely unclear, however, as far as the opioid reward process 
and NO are concerned. Thus, the present study was addressed 
to investigate whether NO is involved in the mechanisms that 
mediate the rewarding effects of morphine. We studied the 
influence of NO synthase inhibitor I-/V-nitroarginiuc (t.-
NOARG) on morphine-induced conditioned place preference 
(CPP) in rats. 
Ml-1 MODS 
Animals 
Male VVistar rats weighing 2-15-405 g were used. The rats 
were housed in groups of lour lo live with food and water 
available ad lib, under a 12 L : 12 D cycle (lights on at 0700 h). 
The experiments were carried out during the light phase of the 
cycle. 
1 To whom requests for reprints should be addressed. 
Drugs 
Morphine sulfate (ampoules containing 20 mg/ml of mor­
phine sulfate; Antigen Pharmaceuticals, Roscrea, Ireland) was 
dissolved in 0.9% NaCI solution and injected in a volume of I 
ml/kg, SC, into the neck region. The dose of morphine refers 
to the amount of the free base. i.-NOARG (Sigma Chemical 
Co., St. Louis, MO) was administered IP in a volume of 2 
ml/kg as 2.5% Tween 80 solution. 
Place Preference Apparatus 
The apparatus consisted of two square-base compartments 
(H 40 x 30 x 30 cm), one with white and the other with gray 
walls and floor. Compartments were separated by a guillotine 
door and covered with a transparent Plexiglas ceiling. The 
apparatus was placed into a dimly lit room. 
Experimental Procedure 
Before starting the experiment, the nits were acclimated to 
experimenter contact for 3 days by handling and weighing 
in the experiment room. The experiment consisted of three 
phases. 
/'reconditioning. During 3 days (days I, 2, and 3), rats 
were given free access to both compartments of the apparatus 
for 15 min each day. On day 3, the time spent by rats in each 
compartment was recorded (the position of the rat was defined 
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by the position of its front paws) and these values served as a 
baseline. According to the baseline values, the animals were 
divided into treatment groups with similar initial preference. 
Because most of the rats (5i from 56 animals) preferred the 
gray compartment (i.e., they spent over 50*/« of time on that 
side), the ones preferring the while compartment were ex­
cluded from the experiment. 
Conditioning. Conditioning was conducted during 4 days 
(days 4, 5, 6, and 7) and included two sessions each day. The 
rats were conditioned for 45 min in the initially nonpreferred 
compartment immediately after administnition of morphine, 
and in the preferred one after administration of saline. An 
interval of 4 h separated the two sessions. The order of mor­
phine and saline presentation, paired with the given environ­
ment, was balanced across treatment groups. L-NOARG (or 
its vehicle) was given 15 min before morphine (or saline) ad­
ministration. The following treatment groups were included: 
a) control [i.e., the animals receiving L-NOARG vehicle pre-
treatment, and saline immediately before the conditioning ses­
sion (veh + sal)]; b) L-NOARG 5 mg/kg plus saline (N5 + 
sal); c) L-NOARG 20 mg/kg plus saline (N20 + sal); d) vehi­
cle + morphine 3 mg/kg (veh + Mo); e) L-NOARG 5 mg/kg 
plus morphine 3 mg/kg (N5 + Mo); and 0 L-NOARG 20 
mg/kg + morphine 3 mg/kg (N20 + Mo). The dose of mor­
phine (3 mg/kg, SC) was selected according to earlier studies 
(11) in which it was shown to produce reliable CPP. 
Postconditioning. The postconditioning test was carried 
out on day 8 (24 h after the last drug administration). No 
injections were given before test. The rats had free choice in 
the apparatus for 15 min, and the time spent in each compart­
ment was recorded by an observer unaware of the previous 
drug treatment. 
Statistics 
The data were subjected to two-factor analysis of covari-
ance (ANCOVA) according to a 3 x 2 factorial design, in 
which the time spent in the drug-paired compartment during 
the postconditioning test served as the dependent variable, 
L-NOARG and morphine as categoric variables, and the base­
line as covariate. Posthoc comparisons were conducted by us­
ing the contrast analysis with Bonferroni levels (i.e., the criti­
cal level 0.05 was divided by the number of the comparisons 
made). 
RESULTS 
Figure 1 shows the results. ANCOVA revealed a significant 
effect for the morphine factor [F(l, 44) = 13.5, p = 0.001] 
indicating that morphine brought about reliable CPP. In addi­
tion, a significant effect [F(2, 44) = 3.2, p = 0.049] was es­
tablished for L-NOARG and a nearly significant one for the 
L-NOARG x Morphine interaction [/7(2, 44) = 2.9, p = 
0.066]. To further clarify the nature of these effects, four 
posthoc comparisons were conducted: the groups N5 + sal 
and N20 + sal were tested against the group veh + sal, 
whereas the groups N5 + Mo and N20 + Mo against the 
group veh + Mo. In most cases, no significant differences 
were found [F(l, 44) = 0.02-0.5, p = 0.48-0.88], However, 
for the comparison of N20 + Mo vs. sal + Mo, the contrast 
analysis revealed F( 1, 44) = 11.6, p = 0.001. This can be 
considered significant, as it is well below the corresponding 
critical p value of 0.0125 for four comparisons. Thus, 
L-NOARG when given at 20 mg/kg reliably attenuated the 
effect of morphine. 
DISCUSSION 
In accordance with previous studies, morphine given 3 
mg/kg, SC, induced reliable CPP (11,14). This effect of mor­
phine was significantly attenuated by NO synthase inhibitor 
L-NOARG given at 20 mg/kg, IP. L-NOARG itself appeared 
to have no reliable affect on place conditioning. 
Because in our apparatus most of the rats prefer one partic­
ular (i.e., the gray) compartment, we ran the biased type of 
place conditioning (i.e., drug treatment was paired with the 
less preferred side). Such a type of procedure has been a mat­
ter for discussion, as antiaversive rather than rewarding prop­
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FIG. 1. Effect of NO synthase inhibitor L-NOARG on place preference 
induced by morphine (3 mg/kg, SC). The columns depict the mean ± 
±SEM time spent in the initially nonpreferred (i.e., drug-paired) compart­
ment during pre- and postconditioning tests (open and closed columns, re­
spectively). The number of animals is given in brackets, sal. Saline; veh, 
vehicle; Mo, morphine; N5, L-NOARG 5 mg/kg, IP; N20, L-NOARG 20 
mg/kg, IP. *p < 0.05 compared with the group veh + Mo (contrast analy­
sis with Bonferroni adjustment). 
NO AND MORPHINE-INDUCED PLACE PREFERENCE 1015 
erties of a given drug may be regarded as determinative (14). 
An optimal way has been proposed to counterbalance the drug 
treatment between the nonpreferred and preferred sides (3). 
With morphine, however, the experiments comparing the bi­
ased and counterbalanced procedures have provided consis­
tent results (1,7). 
The nature of L-NOARG'S influence on morphine-induced 
CPP is a rather perplexing question, because several processes 
may underlie this effect. The acquisition of CPP thus involves 
both mnemonic and motivational components, which can be 
manipulated separately (15). Since NO is involved in long-
term potentiation (12), t.-NOARG may have impaired the ac­
quisition of CPP as a result of its impact on mnemonic pro­
cesses rather than interference with motivational properties of 
morphine. The role of NO in different forms of learning and 
memory, however, is still somewhat problematic. In the study 
by Böhme et ai. (2), t.-NOARG in the dose 25 mg/kg (i.e., 
similar to the one effective in the present study) given IP over 
4 days was ineffective both in impairing radial-maze learning 
in rats and blocking LTP in ex vivo prepared hippocanipal 
slices. The same dose almost totally inhibits brain NO syn­
thase activity (10). This suggests that the observed inhibition 
of morphine-induced CPP cannot be explained solely by the 
impairment of mnemonic processes, and hence, our finding 
may have been based on the changes in the motivational prop­
erties of morphine. 
Brain dopamine has been proposed to be a common neural 
substrate mediating the rewarding properties of different classes 
of abused drugs including opioids (16). NO release-inducing 
agents sodium nitroprusside and L-arginine have been shown to 
enhance the release of dopamine in striatal slices (17). However, 
as far as the reward process is concerned, the inhibition of NO 
synthesis failed to affect dopaminc-dependent lateral hypothala­
mic brain stimulation reward (4). The role of dopamine in opioid 
reinforcement is, in fact, a fairly obscure question, and several 
studies refer to the existence of dopamine-independent compo­
nents (e.g., (9)]. Hence, supposing that there is no commitment 
of NO in the dopamine-related reward process, it is possible that 
NO is involved in dopamine-independent mechanisms of opioid 
reward. 
There are, however, alternative explanations for our find­
ing, which cannot be excluded on the basis of the present 
study. First, L-NOARG may have altered the pharmacokinet­
ics of morphine as a result of its vascular effects. Behavioural 
results suggest that the pharmacokinetic area under the curve 
of cocaine was unaffected by the inhibition of NO synthase 
(4); yet, it does not imply morphine. Second, t.-NOARG may 
have interfered with the cffect of morphine as a result of the 
inhibition of locomotor activity (13). However, at least the 
acute effect of Ihe drug on motor behaviour may be ruled out, 
as the postconditioning test was carried out 24 h alter the last 
I.-NOARG administration. Moreover, the decreased locomo­
tor activity has been shown lo enhance the expression of mor­
phine-induced CPP (8). Third, t.-NOARG could have inter­
fered with morphine-induced CPP as a result of some of its 
(possibly peripheral) aversive properties. In the present study, 
this effect could have been dampened by a possible floor ef­
fect, because the biased type of CPP was used. However, 
in our recent experiments, L-NOARG, when paired with the 
initially preferred compartment, failed to have any reliable 
place conditioning effect (unpublished results). 
In conclusion, the main finding of the present study is that 
NO synthesis inhibition antagonizes the rewarding effects of 
morphine as revealed by the CPP paradigm. Our results refer to 
the potential involvement of NO in the opioid reward process. 
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Summary. The present study was undertaken to deter­
mine the state of sensitivity of dopamine D2/D3 recep­
tors involved in the mediation of yawning behaviour at 
various times following acute morphine administration to 
rats. Morphine (3.0 mg/kg, s.c.) induced a biphasic effect 
on locomotor activity: an initial inhibitory phase lasting 
for about 30 min was after about an hour followed by a 
phase of locomotor activation lasting for about 60 min. 
Dopamine D2/D3 receptor agonist quinpirole 
(0.01-0.1 mg/kg, s.c.) induced yawning behaviour in 
rats. Morphine given at 15 or 60 min before (inhibitory 
phase) inhibited the yawning response to quinpirole 
(0.1 mg/kg) but not when given at 90 or 120 min before 
(stimulatory phase). Naloxone (1.0 mg/kg) given 10 min 
before quinpirole restored yawning inhibited by morphine 
pretreatment during the inhibitory phase (15-60 min 
after morphine). However, during the morphine-induced 
stimulatory phase naloxone strongly inhibited the yawn­
ing response to quinpirole. Dl receptor antagonist 
SCH 23390 [R-( + )-8-chloro-2,3,4,5-tetrahydro-3-methyl-
5-phenyl-1 H-3-benzazepin-7-oI hemimaleate] at 0.01 mg/ 
kg did not affect quinpirole-induced yawning or its inhi­
bition by morphine. However, in rats which received mor­
phine 90 min prior to testing yawning, SCH 23390 en­
hanced quinpirole-induced yawning behaviour as com­
pared with morphine- or saline-pretreated animals. The 
data obtained in the present study indicate that morphine 
pretreatment initially induces a lack of responsiveness of 
the D2/D3 receptors mediating yawning behaviour and 
subsequently increases their sensitivity. However, the 
behavioural expression of hypersensitivity of these recep­
tors seems to be attenuated by the concomitant activation 
of D 1 receptors after morphine pretreatment, and thus 
the enhanced response to quinpirole is first seen after 
blockade of D 1 receptors. 
Key words: Morphine - Naloxone - Quinpirole -
SCH 23390 - Yawning - D2/D 3 receptor hypersensi­
tivity 
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Introduction 
Brain dopaminergic systems have been widely implicated 
in the behavioural effects of opioids (Shippenberg and 
Herz 1987; for review see also Feigenbaum and Yanai 
1984; Ahtee and Attila 1987). It has been suggested that 
acute and chronic opioid administration might change 
the sensitivity of dopamine receptors (Carlson and 
Almasi 1979; Tye et al. 1979; De la Baume et ai. 1979; 
Martin and Takemori 1985, 1987). Further, acute mor­
phine administration increases the dose of haloperidol re­
quired to inhibit apomorphine-induced climbing behav­
iour in mice (Martin and Takemori 1987), prolongs the 
apomorphine-induced stereotypies (Vedernikov 1970) 
and increases apomorphine-induced locomotor activity 
in rats (Martin and Takemori 1985) suggesting an in­
creased sensitivity of postsynaptic dopamine receptors. 
A number of behavioural studies have suggested that 
intense stereotypy and climbing behaviour seen after ad­
ministration of dopamine receptor agonists are depen­
dent on the concurrent activation of both Dl and D2 
types of dopamine receptors (Clark and While 1987; 
Vasse et al. 1988; Dall'Olio et al. 1988). Therefore it is 
difficult to establish on the basis of ihe studies where 
stereotypy or climbing behaviour were taken as the mea­
sures of dopamine receptor sensitivity which receptor 
subtype is responsible for the observed behavioural 
supersensitivity after acute morphine administration. 
The selective dopamine D2 receptor agonist, quinpirole, 
in low doses acts selectively at presynaptic D2 receptors 
and, like many other dopamine D2 receptor agonists, in­
duces yawning behaviour, but in contrast to mixed 
DI/D2 receptor agonist apomorphine, does not induce 
intense stereotyped behaviour (Tsuruta et al. 1981; Stoof 
and Kebabian 1984). Such a feature makes quinpirole a 
valuable tool for studying the sensitivity of dopamine D2 
receptors mediating yawning behaviour. Although it was 
initially suggested (Mogilnicka and Klimeck 1977) and 
supported by later studies (Dourish and Hutson 1985; 
Stoessl et al, 1987) that yawning response is mediated via 
D2 autoreceptors, the data obiained recently (Serra el al. 
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1986; for review see also Stähle 1992) suggest in favour of 
postsynaptic localization of the dopamine receptors me­
diating yawning. Furthermore, recently it was shown that 
quinpirole has about 100 times higher affinity at D3 re­
ceptors than at D2 receptors (Sokoloff et al. 1990). 
Therefore it is not excluded that some of the behavioural 
(yawning?) and biochemical effects of quinpirole might 
be attributed to its action at D3 receptors. The biphasic 
effect of morphine on locomotor activity of rats which is 
well documented (Babbini and Davis 1972; Smee and 
Overstreet 1976; Gen? et al. 1983) might be due to 
changes in dopamine receptor sensitivity. In the present 
study we examined changes in the sensitivity of D2/D3 
receptors by scoring quinpirole-induced yawning behav­
iour after acute morphine administration during both 
phases, the initial phase of locomotor inhibition and the 
later stimulatory phase. 
We and others previously showed that activation of 
D1 receptor inhibits yawning behaviour (Zharkovsky and 
Cereska 1989; Yamada et al. 1990b). Furthermore; D1 re­
ceptor might be involved in the morphine-induced hyper-
motility (Longoni et al. 1987). Therefore, we examined 
the role of D1 receptor in the expression of quinpirole-in-
duced yawning behaviour in morphine preteated rats. We 
used a selective D1 receptor antagonist SCH 23390 [R-
(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-lH-3-
benzazepin-7-ol hemimaleate]. In radioligand binding 
studies and adenylate cyclase assays SCH 23390 has been 
shown to interact selectively with D1 receptors with much 
lower affinity at a2-adrenoceptor, 5-HT2, D2 and D3 re­
ceptors (Hyttel 1983; Iorio et al. 1983; Sokoloff et al. 
1990). 
Materials and methods 
Animals. Male Wistar rats weighing 200-300 g housed in groups of 6, 
with free access to standard rat diet and tap water, in a room with 12 h 
light-dark cycle (lights on at 6.00 h). All behavioural experiments were 
performed between 9.00 and 13.00 h. 
Behavioural studies. Locomotor activity was measured in a microcom­
puter controlled photocell activity monitor containing 5 plexiglass ac­
tivity boxes of 31 x 21 x20 cm (one rat per box). Locomotor activity was 
monitored every 30 min during 180 min after morphine administration. 
The rats had no previous experience with the box and were placed in it 
immediately after morphine injection. 
To assess yawning the rats were placed individually in the similar 
boxes immediately after quinpirole injection. The number of yawning 
episodes was recorded during 30 min after quinpirole administration. 
The intensity of stereotypy was rated on fourpoint severity scale 20 min 
after quinpirole administration by two independent observers. The fol­
lowing scoring system was adopted. 0 = No stereotypy; 1 = periodic 
sniffing with some locomotion; 3 = periodic biting, gnawing or licking; 
4 = continuous (1 min) biting, gnawing or licking, no locomotion 
(Costall et ai. 1977). 
Drugs. Morphine hydrochloride (Ph. Eur. 2nd ed.) was dissolved in 
0.9976 NaCl solution (saline) and injected s.c. in the back of the neck in 
the volume of 2 ml/kg body weight. The doses of morphine refer to the 
base. Quinpirole-HCl (gift of Eli Lilly & Co, Indianapolis, Ind., USA), 
Dl receptor antagonist SCH23390 maleate (gift of Schering Corp., 
Bloomfield; N.J., USA) and naloxone hydrochloride (Sigma, St. Louis, 
Mo., USA) were dissolved in saline and administered s.c. in the volume 
of 1 ml/kg body weight. SCH 23390 was administered 15 min and 
naloxone 10 min prior to quinpirole administration. 
Statistics. Locomotor activity data were analysed by Student's /-test. 
Data from yawning were analysed by the analysis of variance. If it was 
significant, individual group comparisons were made by using 
Newman-Keuls test. 
Results 
Effect of morphine on locomotor activity 
and quinpirole-induced yawning 
In order to determine the pattern and duration of mor-
phine-induced changes of locomotor activity, in the pilot 
experiment animals were administered morphine 
(3 mg/kg) and their locomotion was measured during 
180 min thereafter. Morphine induced a clear biphasic ef­
fect on locomotor activity of rats (Fig. 1). An initial 
phase of immobility that persisted up to 30 min was turn­
ed in about an hour into a significant increase in activity 
lasting for about 60 min and then locomotor activity re­
turned to control level at about 180 min after morphine 
administration. 
Quinpirole over a wide range of doses (0.01 -0.1 mg/ 
kg) induced in rats yawning behaviour with maximum ef­
fects occurring at doses 0.05-0.1 mg/kg (Fig. 2). Further 
increasing the dose of quinpirole led to diminution of the 
yawning response and appearance of low intensity stereo­
typed behaviour. 
In order to explore the effect of morphine on quin­
pirole-induced yawning, we administered 0.1 mg/kg of 
quinpirole at 15, 60, 90 and 120 min following morphine 
and counted yawnings for 30 min after quinpirole admin­
istration. The intensity of quinpirole-induced yawning 
behaviour was dependent on the time interval between 
morphine and quinpirole administration. Figure 3 shows 
that the quinpirole-induced yawnings were nearly totally 
inhibited when quinpirole was administered at 15 min af­
ter morphine and then returned to control level gradually 
with lengthening the interval between morphine and 
quinpirole administration. When quinpirole was adminis­
tered at 90 and 120 min after morphine the number of 
yawns did not differ from control. 
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Fig. 1. Morphine-induced changes in the locomotor activity of rats. 
Locomotor activity was scored for every 30 min during 180 min follow­
ing morphine (3.0 mg/kg, s.c.). Control rats (open columns) were given 
saline s.c. The values given are means±SEM, n= 10. *P<0.05; 
**P<0.01 as compared with corresponding control (Student's /-test) 
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Fig. 2. Dose-response relationship of quinpirole-induced yawnings and 
stereotypies in rats. The values are means±SEM. Each group consists 
of 6-10 animals. *P<0.05; **P<0.01 as compared with control 
(1.2±0.4 yawns/30 min; Newman-Keuls test). No stereotypies could be 
observed in control animals. A Yawning, A stereotypy 
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Fi(j. 3. Effect of morphine pretreatment on quinpirole-induced yawning 
behaviour in rats. Quinpirole (0.1 mg/kg, s.c.) was administered at vari­
ous times (15- 120 min) following morphine (3.0 mg/kg, s.c.), Control 
rats were given saline s.c. followed by quinpirole. Values are 
means±SHM. Each group consists of 8-12 animals. * /><0.05; 
" /'<0.0l compared with saline-treated control group (Ncwman-Keuls 
test) 
Effect of naloxone on quinpirole-induced yawnings 
in morphine pretreated rats 
Naloxone in the dose of 1 mg/kg 10-in before quinpirole 
did not alter the yawning response of the control rats, but 
restored yawnings inhibited by morphine administered at 
15 min before quinpirole (Fig.4A). By contrast, in rats 
given quinpirole 90 min after morphine naloxone totally 
inhibited yawning response (Fig. 4B). When this experi­
ment was repeated in rats 150 min after morphine 
pretreatment neither morphine nor naloxone altered ihe 
quinpirole-induced yawning response (Fig, 4c). 
Effect of SCH 23390 on quinpirole-induced yawnings 
in morphine pretreated rats 
SCH 23390 given alone in the dose of 0.01 mg/kg did not 
affect quinpirole-induced yawning. Neither did 
SCH 23390 given simultaneously with morphine affect 
morphine-induced inhibition of yawning response tesied 
at 15-45 min after morphine (Fig. 5 A). However, when 
SCH 23390 was administered to rats which had received 
morphine 90 min prior to testing, it clearly enhanced 
Morphine+quinpiro1 
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Fig. 4A-C Effect of naloxone on yawning behaviour in rats treated 
with morphine (3.0mg/kg, s.c.). Quinpirole (0.1 mg/kg, s.c.) was ad­
ministered at 15 min (A), 90min (B) or I50min (C) after morphine. 
Naloxone (1.0mg/kg, s.c.) was administered 10min before quinpirole. 
The values are means±SEM. Each group consists of 6-8 animals. 
** P <0.01 compared with control + quinpirole group; " P < 0.01 com­
pared with morphine + quinpirole pretreated group (Ncwman-Keuls 
test) 
yawning (ANOVA: F{ 1.25) = 4.9, quinpirole-induced 
P< 0.05; Fig. 5B). 
Discussion 
In accordance with previous studies (Babbini and Davis 
1972; Smee and Overstreet 1976; Gen? et al. 1983) mor­
phine in our experiments produced a biphasic effect on 
the locomotion of rats. An initial phase of inhibition last­
ing for about 30 min was followed after an hour by a peri­
od of locomotor stimulation lasting for about 60 min. In 
accordance with previous studies quinpirole induccd 
yawning behaviour with maximum effect at 
0.05-0.1 mg/kg. The phase of morphine-induced loco­
motor inhibition was accompanied by a decrease in quin­
pirole-induced yawning behaviour. A similar inhibition 
of apomorphine-induced yawnings by morphine was 
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Fig. 5. Effect SCH 23390 on yawning behaviour in rats treated with 
morphine (3 mg/kg, s.c.) at 15 min (A) or 90 min (IB) before quinpirole 
(0.1 mg/kg, s.c.). SCH23390 (0.01 mg/kg) waü administered s.c. 
15 min before quinpirole. The values are means ± SEM. Each group con­
sists of 8 animals. * P <0.05; ** ,P<0.01 compared with control + quin­
pirole group (Newman-Keuls test) 
found previously (Berendsen and Gower 1986). This in­
hibitory effect of morphine was reversed by naloxone in­
dicating that opioid receptors are involved in the inhibito­
ry action of morphine on yawning behaviour. When 
quinpirole was administered during the phase of 
locomotor stimulation (90 min after morphine) quin-
pirole-induced yawning behaviour wa.s only slightly 
weakened. Naloxone administered during this phase in­
stead of antagonizing the action of morphine, further in­
hibited quinpirole-induced yawning behaviour. When 
quinpirole was given at 150 min after morphine naloxone 
did not alter yawning behaviour showing that opioid 
mechanisms were restored at this time. These data indi­
cate that naloxone, depending on the duration of mor­
phine pretreatment produces opposite effects on D2/D3 
receptor-mediated yawning behaviour: restores yawnings 
during the first (inhibitory) phase and inhibits them dur­
ing the second (stimulatory) phase. 
The phase of locomotor stimulation might represent 
an adaptive phase which develops in response to the ini­
tial phase of morphine-induced locomotor inhibition. 
One possible explanation for the dual effect of naloxone 
is that it might enhance this adaptive response by induc­
ing an additional activation of neuronal mechanisms re­
sponsible for the inhibition of yawnings. Such a possibili­
ty was thought to be unlikely to explain biphasic effect of 
morphine on locomotor activity (Havemann and 
Kuschinsky 1982). According to these authors (see also 
Möller and Kuschinsky 1986) the different sets of opioid 
receptors with different location in respect to dopaminer­
gic system are involved in the mediation of akinesia, mus­
cular rigidity and locomotor activation. Other neuro­
transmitter systems as well as different brain structures 
also might be involved in the naloxone-induced inhibition 
of quinpirole-induced yawning reported here. For exam­
ple, during the phase of locomotor stimulation naloxone 
might activate noradrenergic system (Ayhan and Randrup 
1973; Yamada et al. 1990 a) or inhibit oxytocin release 
(Melis et al. 1989) and thus reduce yawning. 
Also, the observed naloxone-induced inhibition of 
quinpirole yawnings during the phase of locomotor acti­
vation after acute morphine might be due to an activation 
of postsynaptic dopamine D1 receptors. Recent studies 
have shown that morphine-induced behavioural activa­
tion is strongly inhibited by SCH 23390 (Longoni et al. 
1987) suggesting that activation of D1 receptor might be 
involved in locomotor effects of morphine. Our previous 
study showed that administration of D1 receptor agonist 
SKF 38393 inhibited apomorphine-induced yawning, and 
D1 receptor antagonist SCH 23390 antagonised this ef­
fect of SKF 38393 restoring yawning behaviour (Zharkov-
sky and Cereska 1989). In the present study SCH 23390 
in a dose which did not affect yawning in control animals, 
strongly enhanced it in morphine pretreated rats during 
the phase of locomotor stimulation. This finding con­
trasts the data found by Serra et al. (1987) that 
SCH 23390 inhibited quinpirole-induced yawning. How­
ever, the doses of SCH 23390 used by these authors were 
somewhat higher than those used in the present study. 
The enhancement of quinpirole-induced yawning by 
SCH 23390 in morphine pretreated rats suggests that the 
intensity of quinpirole-induced yawning behaviour in 
morphine pretreated rats is dependent on the activity of 
D1 receptor. The activation of D1 receptor seems to oc­
cur in the later phase after morphine administration. 
Such an activation might mask an activation of D2/D3 
receptors mediating yawning behaviour. The activation of 
D1 receptors might develop as a compensatory response 
to their inhibition during the initial hypoactivity phase 
following morphine pretreatment and might be further 
enhanced by naloxone administration. 
In conclusion, our data show that acute morphine ad­
ministration might induce dopamine D2/D3 receptor 
hypersensitivity during morphine-induced phase of loco­
motor activation. However, the expression of D 2/D 3 re­
ceptor mediated behaviour is attenuated by the concomi­
tant activation of postsynaptic D1 receptors. 
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BRAIN dopaminergic systems have been widely implicated 
in the behavioural effects of opioids (4,14,25). Morphine with­
drawal results in a reduction of dopamine (DA) metabolism 
and release (1.3-5,7), which one would expect to lead to super­
sensitive dopamine receptors. The sensitization of DA recep­
tors might be reflected by an enhancement of the behavioural 
effects of DA receptor agonists. However, behavioural studies 
in morphine-withdrawn animals, where DA receptor agonist 
apomorphine was used, provided controversial results. While 
most authors (8.9.13.27.35) found an enhancement of apomor­
phine-induced stereotypy, climbing, and locomotor activity 
during morphine withdrawal, some studies (21) failed to detect 
any changes in apomorphine-induced stereotypy. 
The studies of the behavioural supersensitivity to DA re­
ceptor agonists in morphine-withdrawn animals are compli­
cated by the existence of the multiple DA receptors within 
the central nervous system. DA receptors have been classified 
Pharmacology Biochemistry & Behavior, Vol. 54, No. 4, pp. 787-792. 1996 
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into two major classes, Drlike (D,, D5) and D2-like (D2A, D2B, 
D3, D4) receptors (28,30,33,34,36). Postsynaptic DA receptors 
are represented by D,- and D2-like receptors and they are 
involved in the mediation of behavioural effects of high doses 
of apomorphine (12,23,26,37). Presynaptic receptors (autore­
ceptors) are presumably D2-like and their activation seems to 
result in the inhibition of DA release and metabolism (2,6.10, 
26). There is some evidence suggesting that inhibition of loco­
motor activity and induction of yawning are also mediated via 
presynaptic D2-like receptors (15,16,31,32.39). According to 
other authors (24,29), yawning behaviour is related to the activa­
tion of a distinct subtype of D2-like receptors located postsyn-
aptically. Functionally, post- and presynaptic DA receptors 
play an opposite role in the regulation of dopaminergic neuro­
transmission. Activation of postsynaptic receptors enhances, 
whereas activation of presynaptic receptors inhibits the activ­
ity of the dopaminergic system. Classical DA receptor agonist 
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(0.01-0.1 mg/kg) as well as the intensity of stereotypy induced by a large dose (1.0 mg/kg) of quinpirole. In the morphine-
withdrawn rats the dose of 1 mg/kg of quinpirole caused less yawning than in the control rats, whereas the number of 
erections induced by this dose was enhanced as compared with the control animals. In the control rats the striatal and limbic 
concern rations of dopamine metabolites. 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA). were 
not clearly affected by the smallest dose of quinpirole. However, the small dose of quinpirole (0.01 mg/kg) significantly 
reduced the levels of DOPAC and HVA in the striatum and limbic forebrain of the rats withdrawn from morphine either 
for 24 or 4X h. These findings indicate that withdrawal from repeated morphine treatment enhances the sensitivity of 
dopamine D^-like receptors. 
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apomorphine is regarded as a nonselective DA receptor ago­
nist, because in high doses it acts at both D] and D2 receptors, 
and simultaneous activation of both D, and D2 receptors, lo­
cated postsynaptically, is required for induction of high grade 
stereotypy (12,37). In contrast, another DA receptor agonist, 
quinpirole, possesses rather selective action at D2-like recep­
tors (2834). Similarly to small doses of apomorphine, quinpir­
ole inhibits locomotor activity, induces yawning behaviour, 
and inhibits release and metabolism of D A, but in contrast 
to apomorphine, it does not induce high grade stereotypy even 
in high doses (30,34). Therefore, we used quinpirole to study 
whether the behavioural supersensitivity in morphine-with­
drawn rats is associated with supersensitivity of DA D2-like 
receptors, and investigated the behavioural and neurochemi­
cal effects of quinpirole in rats withdrawn from repeated mor­
phine administration. 
METHOD 
Male Wistar rats, weighing 200-300 g at the start of the 
experiments, were housed in groups of four to six, with free 
access to standard rat diet and tap water, in a room with 12 
L:12 D cycle (lights on at 0600 h). Five separate experiments 
were performed with different groups of animals. In each 
experiment, animals were randomly assigned to two treatment 
groups, saline (control) and morphine. Morphine hydrochlo­
ride (Ph. Eur. 2nd ed.) was dissolved in 0.9% NaCl solution 
(saline) so that the salinity of the solution was isotonic with 
physiological saline. Saline and morphifte were given subcuta-
neously in the back of the neck in the volume of 2 ml/kg body 
weight. The daily dose of morphine was divided in two parts 
and administered at 0800 and 1800 h according to the following 
schedule: day 1:10 and 10 mg/kg; day 2:13 and 10 mg/kg; day 
3:15 and 15 mg/kg; day 4: 20 and 15 mg/kg; day 5: 20 and 20 
mg/kg; day 6: 25 and 20 mg/kg and day 7: 25 and 25 mg/kg. 
On day 8, the animals were given only the morning dose (30 
mg/kg) of morphine and placed back into their home cages 
for 24 or 48 h, and were referred to as morphine-withdrawn 
animals. The doses of morphine refer to the base. Control 
animals were given repeatedly saline. 
Experiment 1 
Twenty-four hours after the last saline or morphine admin­
istration control (n = 22) and morphine-withdrawn (n = 24) 
rats were randomly assigned to three groups each, and re­
ceived quinpirole (quinpirole-HCl, gift of Eli Lilly & Co, Indi­
anapolis, IN) either 0.01,0.1, or 1.0 mg/kg. Immediately after 
that animals were placed into Plexiglas observation boxes of 
31 X 21 X 20 cm (one rat per box). The number of yawning 
episodes and number of erections were counted during 30 
min. Quinpirole was dissolved in saline and administered sub-
cutaneously in the volume of 1 ml/kg body weight. Quinpirole 
doses refer to the salt. The rats had no previous experience 
with the box. 
Experiment 2 
. Twenty-four hours after the last saline or morphine admin­
istration control (n - 10) and morphine-withdrawn (n = 12) 
rats were assigned to two groups each and were given either 
saline or 0.025 mg/kg quinpirole. Immediately after saline or 
quinpirole administrations the locomotor activity of the ani­
mals was measured by a microcomputer controlled photocell 
activity monitor containing five activity boxes of 31 X 21 x 
20 cm (one rat per box). Locomotor activity was monitored 
every 5 min over a 20-min period after quinpirole administra­
tion. The rats had no previous experience with the box. 
Experiment 3 
Twenty-four hours after the last saline or morphine admin­
istration control (n = 8) and morphine-withdrawn {n = 8) 
rats were administered quinpirole (1 mg/kg). Immediately 
after that animals were placed into observation boxes for the 
assessment of stereotypy. The intensity of stereotypy was rated 
on a four-point severity scale over a 60-min period after quin­
pirole administration by two independent observers. The fol­
lowing scoring system was adopted: 0 = no stereotypy; 1 = 
periodic sniffing with some locomotion; 2 = continuous 
sniffing; 3 = periodic biting, gnawing or licking; 4 = continuous 
(1 min) biting, gnawing or licking, no locomotion (11). Ac­
cording to this scoring system scores 1-2 reflect low degree 
stereotypy and scores 3-4 reflect high degree stereotypy. The 
rats had no previous experience with the box. 
Experiment 4 
Twenty-four hours after the last saline or morphine admin­
istration control (n = 22) and morphine-withdrawn rats (n = 
26) were assigned to three groups of 5-11 animals each and 
were administered either saline or 0.01 or 0.1 mg/kg of quinpir­
ole. Animals were decapitated 30 min after quinpirole. The 
striatum and the limbic forebrain were dissected as described 
in detail previously (5). Shortly, beginning at the dorsal surface 
of the rat brain a transverse vertical cut was made 2 mm from 
the pole, just exposing the rostral ends of caudate nuclei. From 
the resulting small piece the area ventral to the rhinal fissure 
was removed and saved as a part of the limbic forebrain. On 
the ventral side of the brain the borders of the olfactory tuber­
cle were cut to a depth of 2 mm, and the brain was turned to 
expose the dorsal surface. Cortical hemispheres were spread 
apart and separated by cutting the corpus callosum, and the 
hippocampi were peeled away from adjacent cortical tissue 
and discarded. The area bordered by the anterior commissure 
and stria terminalis was cut; these cuts continued those made 
earlier around the olfactory tubercle, and the resulting block 
of tissue was removed as the main part of the limbic forebrain. 
The medial borders of the striata were cut free, and the striata 
removed without the underlying cortex. The brain was then 
turned to expose the ventral surface and the amygdalae, situ­
ated on either side of the diencephalon, were pinched off and 
added to the limbic forebrain sample. The weights of striata 
and limbic forebrains were 71.2 ± 8.6 and 172.0 ± 20.9 mg, 
respectively (n = 48, mean ± SD). Each sample was frozen 
immediately on dry ice and stored at -80°C. The concentra­
tions of DA and its metabolites 3,4-dihydroxyphenylacetic 
acid (DOPAC) and homovanillic acid (HVA) were estimated 
by HPLC with electrochemical detection as described by Hai­
kala (18). 
Experiment 5 
Forty-eight hours after the last saline or morphine adminis­
tration control (n = 15) and morphine-withdrawn rats (n = 
15) were assigned to two groups of seven to eight animals 
each and were administered either saline or 0.01 mg/kg of 
quinpirole. Animals were decapitated 30 min after quinpirole. 
The striatum and limbic forebrain were dissected as described 
previously (19) with the difference that amygdaloid nuclei 
from the third rostral slice were discarded. Shortly described, 
the brain was placed on brain mold (RBM-4000C, ASI Instru­
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ments. USA) and sectioned coronally at 2.7, —0.3 and -4.6 
mm from bregma (22). The striata were punched from the 
second rostral slice (2.7 to -0.3) with needle (inner diameter 
3 mm), and the limbic forebrain (containing the nucleus ac-
cumbens and the olfactory tubercle) was dissected from the 
tissue ventral to the striata. The weights of striata and limbic 
forebrains were 23.2 ± 2.2 and 53.6 ± 7.3 mg, respectively (n = 
30. mean ± SD). The smaller tissue weights in Experiment 5 
than in Experiment 4 are due to the fact that only 3 mm-thick 
section of the striata was dissected out in Experiment 5 as 
compared to the whole striata in Experiment 4, and the amyg­
daloid nuclei were discarded from the limbic forebrain sample. 
Further, the samples in Experiment 5 obviously contain less 
surrounding cortical tissues. The concentrations of DA and 
its metabolites were estimated as described above. In spite of 
the different weights of the limbic areas in the two experi­
ments, the amounts of limbic DOPAC and HVA per sample 
were similar in both experiments. 
Statistics 
The yawning and penile erections data were analyzed by 
the Kruskall-Wallis analysis of variance. If it was significant, 
individual group comparisons were made using Mann-
Whitnev U-test at each dose used. The stereotypy data were 
analyzed by the Mann-Whitney l/-test at each time point. 
Locomotor activity data were analyzed by multifactor re­
peated-measures ANOVA [morphine, quinpirole, and time 
(repeated factor) as independent variables]. Concentrations 
of DA metabolites were analyzed by the two-way ANOVA 
followed by the Newman-Keuls test. As the test for interaction 
in the two-way ANOVA at the ordinary significance levels is 
known to be of weak power (17), the significance level of 
0.15 was considered to be appropriate to indicate morphine 
withdrawal x quinpirole interaction (38). 
Experiment 1. Yawning and Penile Erections 
The spontaneous occurrence of yawnings and penile erec­
tions in the morphine-withdrawn rats did not significantly dif­
fer from that in the control rats. The number of yawns in the 
control rats was 1.6 ± 0.7 and in the morphine-withdrawn rats 
0.9 ± 0.3 (Fig. 1). The number of spontaneous penile erections 
was 0.3 ± 0.2 in the control, and 0.4 ± 0.2 in the morphine-
withdrawn rats (Fig. 2). Quinpirole induced a behavioural 
syndrome, which consisted of recurrent yawning and intermit­
tent penile erections accompanied by episodes of grooming. 
The occurrence of yawning episodes and penile erections fol­
lowed inverted U-shaped curve with the maximum effect at 
0.01-0.1 mg/kg of quinpirole, and with a smaller effect at the 
dose 1.0 mg/kg. Morphine-withdrawal enhanced significantly 
the yawning induced by 0.01 and 0.1 mg/kg of quinpirole (Fig. 
1). Higher dose (1 mg/kg) of quinpirole caused significantly 
(p < 0.05) less yawning in the morphine-withdrawn rats than 
in the controls (Fig. 1). In contrast, in the morphine-withdrawn 
animals the number of erections was enhanced after all doses 
(0.01. 0.1. and 1 mg/kg) of quinpirole (Fig. 2). 
Experiment 2. Inhibition of Locomotor Activity 
The locomotor responses to quinpirole in the control and 
in the morphine-withdrawn animals are shown in Fig. 3. 
Multifactor ANOVA with repeated measures revealed an 
overall significant inhibitory effect of both quinpirole, F( 1,28) = 
I I Control Morphine withdrawal 
0.01 0.1 
Quinpirole (mg/kg) 
FIG. 1. Quinpirole-induced yawning behaviour in morphine-with­
drawn rats. Values are means ± SE, n = 8-10 animals. *p < 0.05; 
**p < 0.01 as compared to corresponding control (Mann-Whitney 
U- test). 
10.5, p < 0.01, and morphine withdrawal, F(l, 28) = 10.0, 
p < 0.01, as well as a significant interaction, F( 1, 28) = 6.8. 
p < 0.05. Within group analysis showed that only the effect 
of quinpirole was significantly dependent on time, F(3, 84) = 
7.5, p < 0.05. 
Experiment 3. Stereotypy 
In the control rats the high dose of quinpirole (1 mg/kg) 
induced only low intensity stereotypy as indicated by the 
sniffing episodes. No licking or gnawing could be observed 
after administration .of quinpirole alone. Withdrawal from re­
peated morphine treatment resulted in an enhancement of 
the quinpirole-induced stereotypy. In the morphine-with-
[ j Control I Morphine withdrawal 
0.01 0.1 
Quinpirole (mg/kg) 
FIG. 2. Quinpirole-induced penile erections in morphine-withdrawn 
rats. Values are means ± SE, n = 8-10 animals. *p < 0.05; **p < 
0.01 as compared to corresponding control (Mann-Whitney £/-test). 
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FIG. 3. Effect of quinpirole (0.025 mg/kg SC) on Ihe locomotor activ­
ity in morphine-withdrawn rats. Values are means ± SE, n = 8 animals. 
drawn rats, the stereotyped response was expressed not only 
by the intense sniffing but also by the appcarance of licking 
and occasional gnawing, which contributed to the stereotypy 
score (Fig. 4). 
Experiments 4 and 5. Dopamine Metabolism 
Striatal and limbic DA metabolism was studied in rats 
withdrawn either for 24 or 48 h from repeated morphine treat­
ment. None of the treatments altered the DA concentrations. 
The larger concentrations of the limbic DOPAC and HVA 
in the Experiment 5 than in the Experiment 4 (Table 1) are 
due to the different dissections of the brains in the two experi­
ments (see the Method section). 
Withdrawal from repeated morphine tended to decrease 
the concentrations of DA metabolites (DOPAC: 1-8%; HVA: 
10-17%), but only limbic HVA in Experiment 5 was signifi­
cantly decreased. In the control animals quinpirole, at the 
dose of 0.01 mg/kg, did not significantly reduce the levels 
w ! 
Control Morphine withdrawal 
*« *»  
\i/IN 
i-5 
20 30 40 
Time (min) 
50 
FIG. 4. Quinpirole (1.0 mg/kg SC)-induced stereotypy in morphine-
withdrawn rats. Values are means ± SE, n = 8 animals. *p < 0.05; 
**p < 0.01 (Mann-Whitney U-test). 
DOPAC (5-11%) and HVA (3-6%) except striatal DOPAC 
in Experiment 4 (by 27%; Table 1). The larger dose of quinpir­
ole (0.1 mg/kg) significantly reduced DOPAC (26-32%) and 
HVA (33-35%) in the control animals. The larger dose of 
quinpirole reduced the DA metabolites in the morphine-with­
drawn rats to about same degree as in the control rats (DO­
PAC: 32-46%; HVA 38-40%). When the smaller dose of 
quinpirole (0.01 mg/kg) was given to rats withdrawn from 
morphine for 24 or 48 h the concentrations of striatal (DO­
PAC: 20-29%; HVA: 18-23%) and limbic (DOPAC: 15-26%; 
HVA: 16-26%) DA metabolites were reduced significantly as 
compared with those of morphine-withdrawn rats not given 
quinpirole (Table 1). Furthermore, in the rats withdrawn from 
morphine for 48 h and given quinpirole (0.01 mg/kg) the con­
centrations of limbic and striatal DOPAC and HVA were 
significantly smaller than in the control rats given the same 
dose of quinpirole. However, two-way ANOVA did not reveal 
significant morphine withdrawal X quinpirole interactions us­
ing the ordinary significance level of 0.05. Because both the 
morphine-withdrawal and quinpirole affected DA metabolism 
in the same direction, the test for interaction in the two-way 
ANOVA at the ordinary significance levels is known to be of 
weak power (17). Still, there was a strong tendency of interac­
tion in the levels of limbic HVA at 24 h withdrawal [0.01 mg/ 
kg quinpirole; F( 1, 32) = 2.3, p = 0.14] and of striatal and 
limbic DOPAC at 48 h withdrawal, F(l, 26) = 3.1, p = 0.09: 
F(l, 26) = 2.4, p = 0.14, respectively], indicating that quinpir-
ole's effect was enhanced by withdrawal from morphine. 
The present study shows that withdrawal from repeated 
morphine treatment enhances yawning behaviour and penile 
erections induced by small doses of quinpirole in rats. Thus, 
withdrawal from repeated morphine administration appar­
ently results in hypersensitivity of DA D2-like receptors in­
volved in the mediation of yawning and penile erections. There 
is some controversy concerning the precise location of DA 
receptors mediating yawning response. While some authors 
(16,23,39) think that yawning is mediated via presynaptic re­
ceptors (autoreceptors), others suggest a postsynaptic location 
for the receptors mediating yawning (24,29). 
An enhancement of yawning in the morphine-withdrawn 
rats could be observed only after small doses of quinpirole. 
A large dose (1.0 mg/kg) of quinpirole reduced the yawning 
response in the morphine-withdrawn animals as compared 
with the controls. This observation might be explained by 
the finding of Protais et al. (23), who demonstrated that the 
appearance of stereotypy results in the reduction of yawning 
because these two behaviours are mutually exclusive in rats. 
Thus, the enhancement of stereotyped response observed in 
the morphine-withdrawn rats after a large dose of quinpirole 
mig^it result in the reduction of yawning. In contrast, penile 
erections do not seem to be dependent on the intensity of 
stereotypy because even 1 mg/kg of quinpirole induced more 
penile erections in the morphine-withdrawn animals than in 
the controls. 
The increased score of the stereotyped responses in the 
morphine-withdrawn rats was due to the appearance of the 
elements of high degree stereotypy, licking and gnawing, 
which were not seen in the control rats. Previous studies have 
demonstrated that high degree stereotypy (e.g., continuous 
licking, biting, and gnawing) is induced by coadministration 
of Di receptor agonist SKF 38393 with quinpirole (12,37). This 
suggests that activation of D, receptor plays a permissive role 
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TABLE 1 
EFFECT OF QUINPIROLE ON THE STRIATAL AND LIMBIC CONCENTRATIONS OF 
DOPAC AND HVA OF RATS WITHDRAWN FROM REPEATED SALINE OR 
MORPHINE TREATMENT 
DOPAC (ng/g) HVA (ng/g) 
Quinpirole Morphine Morphine 
mg/kg Control Withdrawal Control Withdrawal 
Experiment 4 (24 h) 
Striatum 
0 1015 ± 50 944 ± 39 808 ± 62 696 ± 48 
0.01 744 ± 53* 672 ± 36* 784 ± 51 570 ± 29* 
0.1 796 ± 49* 642 ± 54* 523 ± 90* 433 ± 37* 
Limbic forebrain 
0 268 ± 12 247 ± 7 233 ± 15 195 ± 13 
0.01 254 ± 7 210 ± 11* 226 ± 11 143 ± 7*t 
0.1 183 ± 21t 133 ± lltS 156 ± 45* 117 ± 15* 
Experiment 5 (48 h) 
Striatum 
0 1269 ± 69 1253 ± 60 849 ± .50 768 i 70 
0.01 1211 ± 56 1003 ± 31tt 800 ± 50 592 ± 32*t 
Limbic forebrain 
0 949 ± 35 877 ± 39 530 ± 31 CO
 
1+
 
0.01 841 ± 43 651 ± 35t§ 497 ± 26 369 ± 17§ 
Quinpirole (0.01 or 0.1 mg/kg SC) was administered at 24 h (Experiment 4) or 48 h 
(Experiment 5) after the last saline or morphine administration, and the rats were decapi­
tated 30 min later. Given are means ± SE, n = 5-13. 
*p < 0.05, tp < 0.01 as compared with corresponding nonquinpirole group (repeated 
saline or repeated morphine). 
tp < 0.05, §p < 0.01 as compared with corresponding control (repeated saline + 
acute saline or quinpirole) group (Newman-Keuls test). 
in the expression of the intense stereotypy induced by D2 
receptor agonists. The appearance of high degree stereotypy 
in the morphine-withdrawn rats was rather unexpected and 
suggested an additional activation of D, receptor. 
The withdrawal from repeated morphine clearly reduced 
the locomotor activity. Although quinpirole significantly in­
hibited locomotor activity in the control rats, it failed to further 
reduce the locomotor activity in the morphine-withdrawn rats. 
This, however, might be explained by the fact that the locomo­
tor activity in these rats was nearly maximally reduced due 
to the morphine withdrawal. Thus, the locomotor activity can­
not be considered as a good indicator of the changes in DA 
receptor sensitivity under our experimental conditions. 
Further, our results suggest that there is an enhancement 
of the effect of quinpirole on the cerebral DA metabolism in 
the morphine withdrawn rats. This enhancement was most 
clearly seen in the rats withdrawn from morphine for 48 h. 
Thus, these findings show that sufficiently long withdrawal from 
morphine augments the effects of quinpirole, and suggest that 
the sensitivity of DA receptors involved in the inhibitory ac­
tion of quinpirole on the DA release and metabolism increases 
during morphine withdrawal. The findings that the D2-like 
receptors involved in the regulation of DA metabolism seem 
to be sensitized later after morphine withdrawal than the re­
ceptors involved in the behavioural actions, agree with the 
time courses of behavioural and neurochemical sensitization 
after withdrawal from psychostimulants (20). 
In conclusion, our data demonstrate that withdrawal from 
repeated morphine treatment induces behavioural supersensi­
tivity to the D2-like agonist quinpirole as reflected by an in­
crease in the number of yawnings and penile erections. Fur­
ther, our data suggest that the DA receptors controlling the 
release and metabolism of the striatal and limbic DA are 
sensitized as well in the morphine-withdrawn rats. 
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Abstract 
PIEPPONEN, T. P., T. KIVASTIK, J. KATAJAMÄKI, A. ZHARKOVSKY AND 
L. AHTEE. Involvement of opioid pi-receptors in morphine-induced place prefer­
ence in rats. PHARMACOL BIOCHEM BEHAV. The main purpose of this study 
was to evaluate the role of |il-opioid receptors in morphine reward. Therefore, we 
studied the ability of (j 1 selective antagonist, naloxonazine (15 mg/kg, IP), to an­
tagonize the conditioned place preference (CPP) induced by morphine (3 mg/kg, 
SC). In addition, effects of naloxonazine on morphine-induced catalepsy 
(15 mg/kg), analgesia (3 mg/kg) and hyperthermia (3 mg/kg) were studied. For 
comparison, the effects of a non-selective opioid receptor antagonist, naltrexone 
(2.5 mg/kg, SC), and a selective 8-opioid receptor antagonist, naltrindole (2 mg/kg, 
IP), on CPP induced by morphine were investigated. Morphine-induced CPP was 
clearly antagonized by pretreatment with naloxonazine and naltrexone (12 h and 
20 min prior to morphine, respectively) but not by naltrindole (15 min before mor­
phine). Naloxonazine also antagonized morphine-induced catalepsy and analgesia 
but not morphine-induced hyperthermia. Naltrindole did not modify morphine-in-
duced catalepsy. These results suggest an active role for pi-opioid receptors in 
morphine reward, whereas morphine-induced hyperthermia does not appear to be 
mediated by jn 1 -opioid receptors. Furthermore, 5-opioid receptors seem to be with­
out significance in morphine-induced reward. 
Naltrexone, Naloxonazine, Naltrindole, Conditioned place preference, Catalepsy, 
Analgesia, Hyperthermia, Opioid receptors 
24 1 
THE ju-opioid receptors are regarded as the primary site of action for the rewarding 
effects of opioids (6). Binding studies have identified two subtypes of fi-opioid re­
ceptors, one, (a 1, with a high affinity for both morphine and enkephalins, and one, 
|i2, with a lower affinity that, however, binds morphine far more potently than it 
binds the enkephalins (42). The pharmacological roles of these subtypes have 
mainly been characterized with the jn 1 -selective antagonist, naloxonazine (29). 
Naloxonazine antagonizes a variety of morphine's actions including analgesia with­
out affecting a number of other ones such as respiratory depression and increased 
striatal dopamine turnover (29). It is not known how these subtypes are involved in 
the rewarding effects of p-receptor activating drugs in rats. Therefore, we have 
studied whether (j 1-receptors are involved in the morphine reward by investigating 
the effect of naloxonazine on morphine-induced conditioned place preference. To 
evaluate the effectiveness and selectivity of the dose of naloxonazine used we also 
measured its effects on morphine-induced antinociception and hyperthermia. In 
smaller doses, systemically given morphine elicits antinociception in rats predomi­
nantly supraspinally through fil-opioid receptors, whereas in larger doses |u2-opioid 
receptors become predominant (35). Morphine-induced hyperthermia is readily an­
tagonized by naloxone (3), which blocks all subtypes of opioid receptors. The pos­
sible role of (il- and ja2-op:ioid receptors in hyperthermia has not been investigated 
prior to this study. 
For comparison, we investigated the effects of the non-selective opioid an­
tagonist, naltrexone, and the selective 8-opioid antagonist, naltrindole, on mor­
phine-induced place preference. Besides the (J-receptor, morphine has some affinity 
to 8-opioid receptors (4), which have been shown to mediate rewarding effects as 
well (12, 33, 36). There is also evidence that in mice blockade of 8-opioid receptors 
prevents rewarding effects of morphine (39). Therefore, to validate the effective­
ness and selectivity of the dose used we also wanted to clarify whether 8-opioid 
receptors are involved in the acute rewarding effects of morphine in rats. 
In rats, large doses of opioids elicit catalepsy (1), a state of immobilization that 
is regarded as a mixture of muscle rigidity and akinesia. Opioid-induced catalepsy 
has been shown to be mediated by fj-opioid receptors, especially by fil-receptors 
(16, 27), whereas the activation of 8-receptors has been shown to mediate only 
stimulatory effects, e.g. locomotor activation and stereotypies (18, 24). Therefore, 
to validate the effectiveness and selectivity of the doses used we also studied the 
effects of naloxonazine and naltrindole on morphine-induced catalepsy. 
METHOD 
Animals 
Male Wistar rats weighing 250-400 g were used. The rats were housed in 
groups of four to six under a 12 L : 12 D cycle (lights on at 0600) with food and 
water ad lib. The experiments were carried out during the light phase of the cycle. 
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Catalepsy 
Catalepsy was measured every 30 min for 150 min after the administration of 
morphine (15 mg/kg, SC). Four tests were used: (1) both front limbs of the rat were 
gently placed onto a 3 cm high horizontal bar; (2) onto a 9 cm high bar; (3) the front 
and hind limbs were placed onto parallel horizontal bars with a 6 cm distance be­
tween bars; (4) the rat was placed on a metal grid positioned at an angle of 45°. 
Each test was scored from 0 to 2; a score of 1 was given if the animal remained 
immobile for 10 s; a score of 2 was given if the animal remained immobile for 20 s 
or more. The four tests were repeated five times during the 2.5 h experiments; the 
scores were summed and taken as a measure of the catalepsy (maximum sum was 
40). Naloxonazine (15 mg/kg, IP) and naltrindole (2 mg/kg, IP) were given 24 h 
and 15 min before morphine, respectively. 
Analgesia testing and rectal temperature measurement 
The pain sensitivity of rats was tested with hot-plate (43). The animals were 
gently placed on a 55 °C copper plate and the time to onset of paw-licking move­
ments was taken as the latency period. The cut-off time was 30 s. Naloxonazine 
(15 mg/kg, IP) was given 12 h prior to morphine (3 mg/kg, SC). Latencies were 
measured 30 and 60 min after administration of morphine. Antinociceptive effect 
was calculated as a percentage of maximum possible effect (% MPE): 
T T T _  T T r  
% MPE =  r A r ^  x 100, 
C T - L N C  
where LTT = latency time of treated animals, LTC = latency before treatment and 
CT = cut-off time. 
Rectal temperature was measured immediately prior to hot-plate test by an elec­
trical thermometer (Ellab, Copenhagen, Denmark) using a 4 cm long rectal probe. 
The animals were unrestrained during measurements. 
Conditioned Place Preference (CPP) 
CPP was studied in an apparatus consisting of two square-base compartments 
(h 40 x 30 x 30 cm), one with white and the other with dark gray walls and floor. 
The compartments were separated by a guillotine door and covered with a transpar­
ent Plexiglass ceiling. The apparatus was placed into a dimly lit room with a mask­
ing noise provided by a ventilation fan. 
3 
Experimental Procedure 
Before starting the experiments, the rats were acclimatised to experimenter con­
tact for 3 days by handling and weighing them. The procedure was similar to that 
described previously (13). 
Each experiment consisted of three phases. 
1. Preconditioning: For 3 days (days 1, 2, and 3) rats were given free access to 
both compartments of the apparatus for 15 min (900 s) each day. On day 3, the time 
spent by the rats in each compartment was recorded and these values served as a 
baseline. 
2. Conditioning was conducted for 4 days (days 4, 5, 6, and 7) and included 
2 sessions each day. Rats were given SC morphine (3 mg/kg) or saline (controls) 
immediately before placing in the nonpreferred compartment for 60 min. After an 
interval of 4 h all the rats were given saline SC and placed in the preferred com­
partment for 60 min. The order of morphine and saline presentation paired with the 
given environment was balanced across treatment groups. Naltrexone (2.5 mg/kg, 
SC), naloxonazine (15 mg/kg, IP) and naltrindole (2 mg/kg, IP) were given 20 min, 
12 h and 15 min prior to morphine, respectively. 
3. Post-conditioning: On day 8, the rats had free choice in the apparatus for 
15 min (no drugs were administered), and the time spent in each compartment was 
recorded. 
Drugs 
Naloxonazine (RBI, Natick, MO, USA) was suspended in 2.5 % Tween® 
80 solution. Naltrindole HCl (RBI, Natick, MO, USA) was dissolved in a 22.5 % 
w/v solution of 2-hydroxypropyl-ß-cyclodextrin. Morphine HCL (Ph. Eur. 2nd ed.) 
and naltrexone HCl (Sigma, MO, USA) were dissolved in saline. Drugs were ad­
ministered at a dose of 2 ml/kg, the doses except for naltrindole are given as a base. 
Statistics 
The data obtained in CPP experiments were subjected to 2-way analysis of co-
variance (ANCOVA), the baseline serving as a covariate. For multiple com­
parisons, the Tukey-compromise post hoc test was used. Data from hot-plate tests 
Were analyzed either with the Wilcoxon signed-rank test (effects of acute drug) or 
the Mann-Whitney U-test (effects of pretreatment). Catalepsy scores were com­
pared with Mann-Whitney U-test. The rectal temperatures were compared with a 
paired t-test (two-tail). 
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RESULTS 
Catalepsy, Antinociception and Rectal Temperature 
Morphine (15 mg/kg, SC) produced a marked cataleptic effect, which lasted for 
about 120 min. This catalepsy was significantly antagonized by naloxonazine (U = 
13.5, p = 0.017 as compared to vehicle pretreatment, Mann-Whitney U-test) but not 
by naltrindole (Fig. 1). 
Naloxonazine clearly antagonized morphine-induced antinociception (Table 1). 
Naloxonazine itself tended to increase the baseline latency (U = 16, p = 0.0924, 
Mann-Whitney U-test). 
Morphine induced a significant hyperthermic effect at 30 and 60 min after its 
administration. Naloxonazine did not alter this effect of morphine (Table 1). 
Place preference conditioning 
In all the experiments, rats treated with morphine showed significant preference 
[F(l, 47) = 5.18, p = 0.0276; F(l, 49) = 12.56, p = 0.0009; F(l, 28) = 23.66, p < 
0.0001, the experiments with naltrexone, naloxonazine and naltrindole, respec­
tively] for the drug associated compartment (Fig. 2). This preference was clearly 
antagonized by both the non-selective opioid antagonist, naltrexone, and the 
|il-receptor selective antagonist, naloxonazine, [F(l, 47) = 8.32, P=0.0059; F(l, 
49)= 3.49, P = 0.0678, the interactions with morphine: F(l, 47) = 10.649, p = 
0.002; F(l, 49) = 6.88, p = 0.012, respectively]. The 6-selective antagonist, naltrin­
dole, did not interact with the effect of morphine, [F(l, 28) = 0.09, p = 0.76, the 
interaction with morphine F(l, 28) = 1.57, p = 0.22]. None of the antagonists alone 
significantly affected the CPP. 
DISCUSSION 
The conditioned place preference (CPP) paradigm has proved to be a valuable 
tool in the investigation of rewarding (or aversive) properties of drugs (for reviews 
see 10,11). In this method the subjects learn to associate the primary rewarding 
stimulus with the environmental stimulus, or in other words, the environmental sec­
ondary stimulus (place) acquires rewarding properties through the conditioning. In 
our experiments the morphine-induced place preference was significantly antago­
nized by the non-selective opioid antagonist, naltrexone, as well as by the pi-opioid 
receptor selective antagonist, naloxonazine. Thus, our results indicate that 
(j 1 -opioid receptors are critically involved in the rewarding properties of morphine. 
This is not surprising because fil-opioid receptors have been shown to be involved 
in natural rewards like feeding (19, 20, 34), drinking (19, 34), and maternal behav­
iour (21). Naloxonazine has also been shown to partially antagonize the increase of 
locomotor activity induced by the selective p-opioid agonist, DAGO (15). Further, 
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rats readily orally self-administer etonitazene (2), a potent opioid, that has recently 
been shown to be rather selective agonist for ja 1-opioid receptor (25). Etonitazene 
also induces CPP (31). Taken together, it seems likely that although pi-selective 
opioid analgesics may lack some undesirable effects like respiratory depression and 
inhibition of gastrointestinal transit, they would not be without rewarding effects. 
Naloxonazine is an azine derivative of naloxone, and in binding studies the be­
haviour of reversibly bound naloxonazine closely resembles that of naloxone, i.e., it 
binds to all types of opioid receptors (9). Only irreversible binding of naloxonazine 
has been shown to be pi-selective, and under in vivo -conditions the best 
pi -selectivity with this drug is reached when it is given about 24 hours before ago­
nist (17). In our experiments naloxonazine was for methodological reasons (to pre­
vent overlapping with conditioning sessions) given 12 h before (except in the cata­
lepsy experiment where it was given 24 h before) morphine. It may be argued that 
at this time (12 h after administration) naloxonazine may have affinity to other 
opioid receptors besides the pl-qpioid receptors. However, the fact that naloxo­
nazine was not able to antagonize morphine-induced hyperthermia, an effect that is 
readily antagonized by the non-selective antagonist naloxone (for an extensive re­
view see 3), strongly indicates its clear selectivity for the putative pi-site using this 
way of administration. Furthermore, our finding suggests that morphine-induced 
hyperthermia is not mediated by pi-receptors. 
In contrast to our findings in rats, in mice the blockade of pi-receptors by 
naloxonazine did not affect morphine-induced CPP (37). This may be because mice 
differ from rats in many respects like in the distribution and proportion of opioid 
receptors in various areas of brain (7, 8, 22, 41). Rats and mice also differ in their 
behavioural response to morphine, large doses of morphine induce catalepsy in rats 
(pi-effect) but locomotor activation in mice (14, 30). Differences in opioid receptor 
mediated functions also occur between different strains of rats, as etonitazene, a 
possible pi-opioid receptor selective agonist, serves as a reinforcer in one rat line 
but not in another one (38). 
Recent reports have emphasized the role of 8-receptor in the rewarding proper­
ties of cocaine (23). Also, 8-receptors have been proposed to mediate rewarding 
effects produced by intra-accumbal morphine (32). Furthermore, 8-opioid antago­
nists were shown to abolish the morphine-induced place preference in mice (39). 
Although the affinity of morphine to 8-receptors is relatively low as compared to 
p-receptors (4), 8-receptors could mediate part of rewarding effects of morphine in 
räts as well. Our results, however, do not support this idea, because naltrindole was 
without effect on morphine-induced CPP. Neither did intracerebral administration 
of 8-antagonist, ICI 174,864, modify the CPP induced by ICV morphine (33). Fur­
thermore, naltrindole affected heroin self-administration only at doses (10 and 
15 mg/kg, 26), which were: 10-1000 fold larger than the ones needed to antagonize 
the antinociception induced by the selective 8-agonists, DPDPE or DSLET (5). As 
naltrindole blocks both putative subtypes (81 and 82) of 8-receptors (28, 40), it 
seems unlikely that 8-opioid receptors are involved in the rewarding effects of mor­
phine in rats. 
6 
In conclusion, our results indicate a distinct role for pi-opioid receptors in the 
rewarding effects of morphine in rats, and 8-opioid receptors appear to be without 
significance in this respect as well as in the mediation of morphine-induced cata­
lepsy. Furthermore, our results confirm that jn 1-opioid receptors play an active role 
in the mediation of morphine-induced antinociception and catalepsy. In contrast, 
|il-opioid receptors do not seem to be involved in the morphine-induced hyper­
thermia. 
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TABLE 1 
The effect of naloxonazine pretreatment (15mg/kg, IP, 12 h) on morphine-induced (3 mg/kg, 
SC) antinociception and hyperthermia. Antinociception was measured by estimating the 
latency (s), and mean percentages of maximum possible effect (% MPE) were calculated. 
The rectal temperatures (Trect, °C) were measured from the same animals immediately be­
fore placing them on the hot plate. The median values ±95% confidence limits (latency and 
%MPE) or the mean values ± SE (Trect°C) of 7-8 animals are given. 
Time after morphine administration 
Pretreatment 0 min 30 min 60 min 
Latency 
Vehicle 8.4±2.9 16.2±3.2 * 9.4±1.4 
Naloxonazine 12.8±3.3 12.3±3.0 10.0±2.9 
% MPE 
Vehicle 31.6±15.1 0.5±14.4 
Naloxonazine 
-12.2±26.1 t -2.6±23.2 
Trect °C 
Vehicle 38.0±0.1 38.6±0.2 * 38.7±0.2 ** 
Naloxonazine 38.3±0.1 38.9±0.1 ** 38.9±0.2 * 
* p < 0.05; ** p < 0.01 vs. corresponding value at 0 min, Wilcoxon signed-rank test (latency 
and % MPE) or Student's paired two tail Mest (Trect). 
^ p < 0.05 vs vehicle pretreatment; Mann-Whitney U-test. 
NALOXONAZINE NALTRINDOLE 
Fig. 1. Effects of opioid antagonists naloxonazine (15 mg/kg, IP, 12 h before morphine) and 
naltrindole (2 mg/kg, IP, 15 min before morphine) on catalepsy induced by morphine 
(15 mg/kg, SC). The control rats received vehicle 12 h or 15 min before morphine, respec­
tively. The columns show the summed catalepsy scores of five measurements at 30 min in­
tervals after morphine administration. The median values ±95% confidence limits are given, 
n=6-9. Abbreviations: VEH = vehicle, MO = morphine, ANT = antagonist. * p<0.05 
(Mann-Whitney U-test). 
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Fig. 2. Effects of opioid antagonists naltrexone (NTX, 2.5 mg/kg SC, panel A), 
naloxonazine (NAZ, 15 mg/kg, IP, panel B) and naltrindole (NTI, 2 mg/kg, IP, panel C) on 
conditioned place preference induced by morphine (3 mg/kg, SC). The antagonists were 
administered 20 min, 12 h, and 15 min before morphine, respectively. The control rats re­
ceived saline (SAL) or vehicle (VEH). The columns show the times (means ± SE) the rats 
(n= 7-18) spent in the initially non-preferred (white) compartment during preconditioning 
(shaded columns) and postconditioning (filled columns). 
* p< 0.05, ** p<0.01 vs control group, o p<0.05, oo /?<0.01 vs morphine group (Tukey-
compromise test). 
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